\sim				
.51	VSTAI	matic	review	/
$\mathbf{\mathcal{C}}$	<i>y</i>	Hanc	100101	,

Colorectal cancer and microbiota modulation for clinical use. A systematic review.

Julio Madrigal-Matute* and Sara Bañón Escandell Biomedical Institute for Nutrition and Health (IBIONS).

*Corresponding author:

Julio Madrigal-Matute, PhD

Biomedical Institute for Nutrition and Health (IBIONS).

Phone: +34606008917;

Madrigal-matute@ibions.com

Abstract

Colorectal cancer is one of the top contributors to the global burden of cancer incidence and mortality with genetic and environmental factors contributing to its etiology. Modifiable or environmental factors can be the cause of up to 60% of the risk of developing colorectal cancer. Hence, there is a growing interest in specifically defining what can be improved in our lifestyle to reduce this risk, improve the effectiveness of treatments, reduce side effects, and decrease the risk of recurrence. One of the elements directly related to lifestyle is gut microbiota. The microbial ecosystem has a vital role in colorectal cancer prevention and antitumoral response through modulation of the immune system and production of short-chain fatty acids. Numerous approaches have been used to identify healthy microbiota that can reduce the risk of cancer development, improve treatment efficacy, and reduce side effects.

Scientific literature in this subject is growing exponentially and, therefore, systematic reviews and meta-analysis are required to ensure that appropriate recommendations are given to patients.

This work aimed to perform a systematic analysis of the published literature to elucidate whether microbiota modulation through pre-, pro-, symbiotic treatment and/or nutritional intervention can be beneficial for patients diagnosed with colorectal cancer.

Detailed analysis of published studies shows that some prebiotics, such as inulin and resistant starch, probiotics such as lactic strains producers of short-chain fatty acids, and consumption of unprocessed plant products, can be effective recommendations for patients diagnosed with colorectal cancer. This advice should always be individually tailored and followed up by a healthcare professional with expertise in the field.

Keywords: cancer, colorectal, nutrition, diet, probiotic, prebiotic, symbiotic, immunotherapy, immune system.

Abbreviations:

CRC, colorectal cancer; ROS, reactive oxygen species; RNS, reactive nitrogen species; MSI, Microsatellite instability; SCFA, Short chain fatty acids; LPS, Lipopolysaccharide; dMMR, deficient DNA mismatch repair; AOM, Azoxymethane; DSS, Dextran sodium sulfate; TNF-α, tumor necrosis factor alpha; MPO, Myeloperoxidase; PCNA, Proliferation cellular nuclear antigen; SLC5A8, Solute Carrier Family 5 Member 8; GPR43, G protein-coupled receptor 43; CEA, Carcinoembryonic antigen: APC, Adenomatous polyposis coli; DHM, 1,2-dimethyl hydrazine; TGF-β, Transforming growth factor beta; TLR2, toll-like receptor 2; DC, dendritic cells; PD-1, Programmed cell death protein 1; PDL-1, Programmed cell death protein ligand 1; CTLA-4, Cytotoxic T-Lymphocyte Associated Protein 4; CYP, Cytochrome P450 Family; GSTM1, Glutathione S-Transferase Mu 1; SULT1, Sulfotransferase Family-1; PYY, Peptide tyrosine; PPARy, peroxisome proliferator activated receptor gamma; 6,BR, 6-bromoisatin; NE, marine extract; MD, Mediterranean diet; LFD, low fat diet; HFD, high fat diet; EPA, Eicosapentanoic acid; PUFA, polyunsaturated fatty acids; CRP, C reactive protein; SFRP2, Secreted Frizzled Related Protein 2; DNMT1, DNA Methyltransferase 1; COX-2, Cyclooxygenase-2; PGE₂, Prostaglandin E2; Cxcl, C-X-C Motif Chemokine Ligand; BCL2 Interacting Killer; KC, Keratinocytes-derived chemokine; Gr-1, Glucocorticoid Receptor-1; CTNNB1, Beta catenin 1; EGFR, Epidermal growth factor receptor; TYMS, Thymidylate Synthetase; LPE, Lisophosphatidiletanolamine; LPC, Lisophosphatidylcholine; G-CSF, Granulocyte Colony-Stimulating Factor; GM-CSF, Granulocyte Macrophage Colony-Stimulating Factor: HDAC, Histone Deacetylase: JAM1, F11 Receptor; 5-FU, 5-florouracil; EGCG, epigallocatechin-3-gallate;

1. Introduction

1

2

3

4

5

6

7 8

9

10

11

12

13

14

15

16

17 18

19

20

21

22

23

24

25

26 27

28

29

30

31

32

33

1.1. Colorectal cancer

Colorectal cancer (CRC) is a disease based on an important genetic component, coupled with key influence from our lifestyle habits. Approximately 10-20% of diagnoses of CRC have a family history with the disease, and through family and twin studies, heritability is estimated to range from 12-35%.^{2, 3} Although numerous genome-wide association studies have been performed identifying genes that increase susceptibility to develop CRC,4 many risk factors remain unknown. However, only 5-7% of patients' colon cancer has a clear genetic origin. Hereditary CRC syndromes can be subdivided into those associated with polyposis and those without polyposis (Lynch syndrome and familial CRC).⁶ Risk factors also include the development of inflammatory bowel disease, including Chron's disease and ulcerative colitis. These pathologies significantly increase the chances of developing CRC, being highly dependent on environmental and nutritional factors. Specifically, geographical differences in incidence of CRC are influenced by genetic, and mainly environmental and nutritional risks.8 It is not surprising that environmental factors have such a strong influence on the risk of developing colon cancer, as the intestinal epithelium is one of the tissues with the highest turnover rate in our body and is in continuous direct contact with nutrients, food toxins, and microbiota. 9-14

Etiology

Among the metabolic changes that precede the development of cancer are chronic cell damage due to a pathological increase in reactive oxygen and nitrogen species (ROS and RNS), DNA damage, and chronic inflammation. 6 Inflammation triggers the release of pro-inflammatory cytokines into the gut to regenerate damaged tissue. In certain situations, inflammation becomes chronic, forming a positive feedback loop that facilitates tumor development.¹⁵ Colon tumors generally begin with the transformation of stem and epithelial cells that reside at the base of the colonic crypts. These cells undergo chronic damage by inflammation, oxidative stress, and/or genetic mutations that evolve into a premalignant lesion or polyp. 16 These polyps follow two main routes of differentiation to malignancy: the adenoma-carcinoma type (70-90%) and the serrated (10-20%) type. In addition, another route not associated

35

36

37

38

39

40

41

42

43

44

45

46

47 48

49

50

51

52

53 54

55

56

57

58

59

60

61 62

63

64 65

66

with polyposis has been described with a lower incidence, characterized by microsatellite instability (MSI; 2-7%).17 The development of a malignant tumor is estimated to take 10-15 years on average.⁶

1.2. Gut microbiota

The microbiome includes all types of microorganisms associated with the host, interacting in a complex way and usually found in the epithelial barrier zones.¹⁸ It is acquired at birth by vertical transmission and is modulated throughout our lives by environmental factors. 19 The microbiota is a dynamic niche that is involved in the maintenance of health and in the origin and development of numerous diseases by modulating the homeostasis of the immune system.²⁰ Although the mechanisms may be varied, one of the most notably is the stimulation of the T-cell response, through the expression of bacterial epitopes or their cross-reactivity with tumor epitopes. Additionally, gut microbiota also modulates the response to tumors by inhibiting specific receptors that promote inflammatory and immune responses. Finally, another important mechanism carried out by the microbiota is the synthesis of metabolites, such as short-chain fatty acids (SCFA), which elicit a local and systemic response in the host organism. 19 But what is the ideal microbiota composition for health? This is a question that is not easy to answer, although numerous studies have attempted.21, 22 Analyzing a metabolite panel comparing stool from healthy versus CRC patients, it was found that the best marker to discern between a healthy patient and a CRC patient is primarily a decrease in the CRC patient's levels of certain SCFA, in particular, acetate and butyrate. 23 The protective effect of SCFA against CRC may be due to their ability to decrease inflammation and modulate the immune response.²⁴ In addition, SCFA inhibit proliferation and promote apoptosis in neoplastic colonocytes.²⁵ SCFA play a key role in maintaining intestinal health and preventing the development of numerous pathologies.²⁶ They are produced by many bacteria in the intestinal tract, in particular, lactic acid bacteria and bifidobacteria. SCFA transporters and their receptors are the communication bridges between the microbiota and the cells of the gut.²⁷ Butyrate has been shown to decrease intestinal inflammation by regulating epithelial occlusive junctions, 28 which are essential for maintaining the integrity of the intestinal barrier and mucosa by aiding in the homeostasis of ions, nutrients and water.²⁹

68

69

70

71

72

73

74

75

76

77

78 79

80

81

82

83

84

85

86

87

88 89

90

91

92

93

94

95

96

97

98

99

Among the SCFA-producing bacteria, and specifically butyrate, are those of the genus Butyricicoccus, which could protect against colitis in patients with irritable bowel syndrome, as these bacteria are reduced in affected patients. 30 Likewise, other bacteria belonging to the phylum Firmicutes such as Eubacterium rectale, Ruminococcus albus, R. callidus, R. bromii and F. prausnitzii are 5 to 10 times more abundant in healthy patients than in patients with Crohn's disease. 31 The decrease in species such as Bacteroides fragilis and B. vulgatus is associated with reduced levels of butyric and propionic acid and increased inflammatory markers.³² Additionally, Akkermansia muciniphila, one of the most abundant components of the intestinal microbiota, is found to be decreased in obese patients.^{33, 34} those with ulcerative colitis, 35 and those with CRC. 36 A. muciniphila ferments mainly mucins, as well as other mono- and polysaccharides, giving rise to various SCFA.³⁷ Taken together, it appears that SCFA-producing bacteria, such as acetate and butyrate are often associated with healthier microbiota profiles. For these reasons, SCFA are being tested as a therapy for CRC.³⁸

Dysbiosis

Pathological changes in the composition of the microbiota is known as dysbiosis.³⁹ This unbalance in the homeostatic microbiome is related to the origin of various types of tumors due, in part, to the modulation of tumor immunity. 40 with CRC being prominent among these tumor types. 41 Patients with CRC are often characterized by a decrease in beneficial microbiota and an increase in pathogenic opportunistic microorganisms.²² This pathogenic imbalance can have a variety of origins. A frequent and often underestimated cause of dysbiosis stems from intensive antibiotic use.42

Chronic intestinal inflammation and epithelial disruption, two of the most important risk factors for CRC development, are related to intestinal dysbiosis. 21, 43 Many of the pathogenic species identified in different studies associated with the development of CRC belong to the group of hydrogen sulfide (H₂S)-producing bacteria. These bacteria can oxidize SCFA, decreasing its levels locally. 44 H₂S is highly toxic to colonocytes, causes damage to the intestinal epithelium, promotes inflammation, produces metabolic changes, especially through oxidation of butyrate, and can result in the development of CRC. 45, 46 H₂S is also rapidly absorbed by the mucosa, 47 which can disrupt the balance between proliferation and apoptosis^{48, 49} and lead to DNA

101

102

103

104

105 106

107

108

109

110

111 112

113 114

115

116

117

118 119

120

121

122

123

124 125

126

127 128

129

130 131

132

damage. 50 Furthermore, feces of people at high risk of CRC recurrence have higher concentrations of H₂S.⁵¹ Other studies corroborate these results by finding an increase in Fusobacterium spp., and more specifically Fusobacterium nucleatum, an H₂S-producing species, in colonic tumor tissue.^{52, 53} F. nucleatum also promotes tumor growth, cell proliferation and the acquisition of chemoresistance in CRC, favoring inflammation and autophagy as a cytoprotective mechanism of the tumor. ⁵⁴,

At the phylum level, CRC patients show increased abundance of Proteobacteria and Verrucomicrobia. 56 Species associated with CRC development include Bacteroides fragilis, Escherichia coli, Peptostreptococcus spp, Enterococcus faecalis, Streptococcus bovis, or Porphyromonas spp.^{22, 53, 57-59} For example, B. fragilis and E. coli play a key role in the development of familial CRC. In patients with adenomatous polyposis, areas arise in the colonic mucosa where B. fragilis and E. coli accumulate, leading to a local increase in oncotoxins such as B. fragilis toxin and colibactin. 60 These oncotoxins, when transferred to the colon of mice, increase colonic tumor growth and mortality. 60 In addition, B. fragilis levels are elevated in patients with diarrhea, with chronic diarrhea being an important risk factor for the development of CRC.61

Nonetheless, it may not be so simple to discern which bacteria are beneficial. In general, it appears that it may be context-dependent and that one of the key characteristics of a healthy microbiota is its beneficial/harmful microbiota ratio and/or its diversity.

1.3. Food and gut microbiota

Due to the importance of the microbiota in health and in the origin of diseases such as CRC, there is much interest in knowing how to modify the flora in order to have a better homeostatic capacity. The main way in which we can interact directly with our microbiota is through the food we eat.⁶² A study of monozygotic and dizygotic twins, and their mothers, shows that while there is a common core microbiota, pathological conditions, such as malnutrition leading to obesity, produce a significant change in the microbiota. These changes result in reduced diversity and modifications in gene expression and metabolic pathways.⁶² Along these lines, it has been shown that a "Western" diet (high fat and sugar) can alter the microbiota in periods as short as 1-3 days, and that these changes can be reversed by following a healthier diet (high

134 135

136

137

138

139 140

141

142

143

144

145

146 147

148

149 150

151

152

153 154

155

156

157

158

159

160

161

162

163

164

165

plant). 63, 64 These results show that a healthy diet, mainly a plant-based, can improve our microbiota faster than probably any other therapeutic intervention. In fact, adherence to a Mediterranean diet has been shown to have a beneficial outcome in modulating the microbiota. Participants following this type of diet had higher levels of SCFA, Prevotella and Firmicutes that degrade plant fibers, in addition to a higher proportion of bifidobacteria/E. coli and better gastrointestinal habits. 65 Therefore, it is likely that part of the health benefits of this dietary pattern are due to its effect on our commensal flora.

In fact, the health benefits of certain dietary patterns, such as fiber consumption, have been evaluated for decades. However, the mechanisms by which fiber decreases the incidence of CRC are not fully understood. Two mechanisms that may be complementary are generally postulated: i) fiber may facilitate gastrointestinal transit decreasing the contact between procancerous substances and ii) the intestinal epithelium, or gut bacteria may ferment fiber, producing SCFA.66 In an attempt to dissect these mechanisms, a study was conducted using a mouse model in which a representative human microbiota (gnobiotic) was "seeded". It was found that a lowfiber diet leads to an overgrowth of bacterial species that cause degradation of the mucus lining the intestinal barrier. This makes the barrier more permeable to pathogenic organisms, facilitating the development of colitis.⁶⁷ In this mouse model, with a low-fiber diet, overgrowth of B. caccae and A. muciniphila was promoted, with these two species being responsible for the degradation of intestinal mucus.

The importance of nutrition is often underestimated in most scientific and medical fields; however, available data show that it is a key tool in modifying the microbiota.

1.4. Probiotics

Probiotics are defined as "live microorganisms that confer a health benefit when administered in adequate amounts". 68 The benefits are varied and range from the maintenance of intestinal homeostasis to the prevention of diarrhea, irritable bowel syndrome, and constipation.⁶⁹ In addition, numerous in vitro,⁷⁰ preclinical⁷¹⁻⁷³ and clinical studies⁷⁴ have shown that probiotics may have beneficial effects, specifically in cases of CRC.

Probiotics exert their beneficial action by modifying the gut microbiota, improving the gut barrier and its microenvironment, secreting anti-cancer metabolites, and reducing inflammation.⁷⁵ In addition, probiotics have an intimate relationship with the

167

168

169

170

171

172

173

174

175

176

177 178

179 180

181

182

183

184

185

186

187 188

189

190

191

192

193

194 195

196

197

198

immune system, particularly through homeostasis of epithelial cell junctions and modulation of T-lymphocytes and dendritic cells activation.^{36, 76} As an example, Butyricicoccus pullicaecorum reduces necrotic enteritis and pathogen abundance in the caecum and ileum in broiler chickens.⁷⁷ Furthermore, its administration promotes the proper functioning of the intestinal epithelial barrier and reduces colitis in preclinical models.³⁰ One of the most widely used probiotics is *A. muciniphila*, which has been shown in numerous studies to have a beneficial role in health maintenance and a therapeutic effect on various diseases such as obesity, ⁷⁸ or epithelial tumors. ⁷⁹, ⁸⁰ In this regard, it has been used in preclinical models of chronic colitis, where it improved inflammatory parameters and damage in the colon.⁸¹ Additionally, lactic acid bacteria have been frequently used for their health benefits and their immunomodulatory effect, 82 contributing to inhibiting the development of pathogens.89 Treatment with L. salivary and L. fermemtum in combination with L. acidophilus can reduce CRC cell proliferation in experimental models.^{83, 84} Furthermore, oral administration of 21 different strains of Lachnospiraceae attenuated colorectal inflammation and improved the composition of the microbiota in preclinical models.85 However, a meta-analysis evaluating the role of probiotics in cancer patients failed to find a clear overall beneficial outcome, except in reducing the degree of diarrhea, bowel movement, and the need for antidiarrheal drugs.86

1.5. Prebiotics

Prebiotics are defined as "any substance that is selectively utilized by the recipient organism and confers a health benefit". 87 One of the most studied prebiotics is inulin. Inulin is part of a group of dietary fibers known as inulin-type fructans. These compounds are found in numerous foods such as garlic, artichoke, onion and asparagus.⁸⁸ Inulin-type fructans resist digestion in the small intestine and are fermented in the colon, where they are transformed into lactic acid and SCFA, improving intestinal health. 89, 90 Inulin has been shown to increase levels of CRCprotective bacteria such as Bifidobacteria, 91 Bacteroides, 92 and Akkermansia muciniphila⁷⁸ in murine models. The role of resistant starch as a prebiotic has also been examined in numerous pathologies and its benefits have also been suggested in the field of cancer, particularly in CRC.93 Resistant starch is a group of carbohydrates that resist

digestion by pancreatic amylase in the small intestine. This type of starch then

199 reaches the colon where it is fermented by the microbiota, producing numerous

200 protective effects against tumor development, including production of SCFA

(butyrate), regulation of bowel movements and the reduction of colonic pH. 93, 94 Many 201

foods contain resistant starch, such as cereals, vegetables, legumes, seeds, and

some nuts. 93, 95 203

202

204

205

206

207

208

209

210 211

212

213

214 215

216

217

218

219 220

221

222

223

224

225 226

227

228

229

230

Recent studies are using prebiotics as a basis for the synthesis of therapeutic

targets for cancer treatment because of their promising role in this field. 96

1.6. Symbiotics

Symbiotics are defined as "a mixture including live microorganisms and substrates, which used selectively by the host organism confers a health benefit". 97 A distinction is made between cooperative symbiotics, in which probiotic and prebiotic are administered together and act independently contributing to the health benefit, and synergistic symbiotics, where the probiotic uses the co-administered prebiotic as a substrate. 97 The use of symbiotics is becoming increasingly common in the biomedical literature as a method of enhancing the effects of pro- and prebiotics used individually. For example, the combination of Bifidobacterium animalis subsp. lactis with a resistant starch led to a decrease in the number and incidence of colon neoplasms. Interestingly, the probiotic alone did not produce a similar effect. It was the combination that resulted in protection against cancer development, in part through increased production of SCFA.98

1.7. Oncological treatments and microbiota in CRC

than pre- or probiotics alone.

Technological advances and new therapies have dramatically increased the life expectancy of CRC patients. 6 However, CRC patients often show particularly low responses to hospital treatments.⁹⁹ For this reason, numerous lines of research are being devoted to better understanding the mechanisms underlying this lack of response to treatments, such as immunotherapy.

Therefore, it seems very promising that symbiotics may play a more effective role

The first evidence showing the key role that the microbiota plays in modulating the body's immune response to cancer treatment came from a pioneering study showing that microbial flora, and in particular lipopolysaccharide (LPS) from Gram-negative bacteria, increased the activation of dendritic cells and TCD8+ lymphocytes. In this

232

233

234

235

236 237

238

239 240

241

242 243

244

245

246

247 248

249

250 251

252 253

254

255

256 257

258

259

260

261

262 263 way, the microbiota promoted melanoma regression after radiotherapy treatment. In contrast, the use of antibiotics, inhibition of LPS and its signaling, significantly diminished the effect of radiotherapy treatment. 100 Numerous studies have corroborated these data, showing that therapies decrease their efficacy in axenic (without microbial flora) or antibiotic-treated mice. 80, 101-103 A key study in this field showed that genetically identical mice from two different suppliers responded unequally to the same cancer treatment, due to differences in microbiota. Not only that, but cohousing or fecal transfer eliminated these differences, clearly pointing towards a key role of microbiota in modulating the efficacy of cancer treatment. 104 Although the role of the microbiota has been studied in different cancer treatments such as radiotherapy, 100 chemotherapy, 102 and surgery, 105 most studies have focused in immunotherapy. 80, 103 This may be due to both the microbiota's promising role in

Immunotherapy

Unfortunately, a large proportion of CRC patients do not respond well to immunotherapy. It is known that the effectiveness of some treatments depends, to a large extent, on the individual's genetics and/or cancer phenotype⁹⁹; however, for a majority of CRC patients, the cause of their lack of response is unknown.

cancer treatment and its key role in modulating the immune response.

Immunotherapy has promising results in numerous tumor types by inducing immunity by T lymphocytes. 106 Thus, the anti-PD-1 drugs pembrolizumab and nivolumab are effective in metastatic patients whose tumors are deficient in DNA mismatch repair (dMMR) enzymes and have high microsatellite instability (MSI-H). ⁹⁹For the treatment of refractory dMMR-MSI-H tumors, pembrolizumab and nivolumab combined with an anti-CTLA4, ipilimumab, are used. However, in tumors with active DNA repair enzymes and low microsatellite instability, which account for 85% all tumors, these therapies tend to be ineffective. 99 Therefore, there is great interest in finding methods to improve the efficacy of these therapies in CRC.

Knowing the ideal composition of microbiota to improve the efficacy of immunotherapy treatments is no easy task. It is likely, as mentioned above, that the key lies in increasing the ratio of bacteria that are beneficial to health and decreasing those that are harmful. 107 In this line, mice transplanted with microbiota from CRC patients show, after treatment with anti-PD-1, a decrease in the anti-tumor response in CRC and lower survival, compared to those transplanted with microbiota from

healthy controls. 117 Among the bacteria that may be beneficial to improve 264

265 immunotherapy are: Clostridiales, Ruminococcacae, Enterococci, Collinsella,

Alistipes, Faecalibacterium spp, A. muciniphila, B. fragilis, Eubacterium linosum or 266

Bifidobacteria, although most studies have been performed on epithelial type

tumors. 19, 79, 80 268

267

269

270

272

274

275

277

278

279

280

281

282

283

284

287

288

292

293

294 295 Therefore, the study of the microbiota in the treatment of cancer patients, especially

in CRC patients whose treatments do not reach the effectiveness of other types of

271 cancer, is essential.

Effect of surgery on the microbiota

273 Colorectal surgery in humans aims for total tumor removal plus the addition of a

safety perimeter. When this clean-border surgery is achieved, the likelihood of tumor

recurrence decreases considerably. 108 However, local recurrences are common, up

276 to 15%, the origin of which appear to be linked to the biology of the primary tumor

and/or seeding of the tumor bed during surgery. 109-111 Most tumors recur at the site of

the anastomosis due to incomplete wound closure, the inherent porosity of the

junctional area, improper healing, and/or the presence of collagenolytic organisms

that increase porosity. 112, 113 In this regard, a high-fat diet increases the production of

colorectal tumors in preclinical models of anastomosis. 105 This mechanism is linked

to the overproduction of collagenolytic organisms at the suture site. Pre-operative

fecal analysis shows that obese patients respond by increasing collagenolytic micro-

organisms after taking antibiotics. In contrast, non-obese patients have decreased

levels of collagenolytic micro-organisms. 105 285

Therefore, a healthy microbiota low in collagenolytic microorganisms is key to 286

increasing the chances of successful CRC surgery and avoiding recurrences.

1.8. Study aims

289 The overall aim of this work is to review published studies on the modification of the

290 microbiota in CRC.

291 The specific objectives of this work are to evaluate the impact of modulating the

microbiota in CRC patients through; 1) probiotics, 2) prebiotics, 3) symbiotics and 4)

nutritional changes. We aim to analyze the potential use of these approaches to

modulate the microbiota in CRC patients.

2. Methods

2.1. Systematic search

- The search strategy was defined between January 15th and April 15th, 2021. The 298
- search and filtering in the Pubmed database took place on April 24th, 2021. The 299
- language used for the search and filtering of the publications was English. The 300
- detailed analysis of the selected publications was carried out from April 25th to May 301
- 31st, 2021. 302

296

297

- 303 The search strategy included six types of terms: (1) target disease of the study: (2)
- 304 type of cancer; (3) microbiota and dysbiosis; (4) oncology treatment, (5) use of
- nutrition and/or supplementation with pro-, pre- and symbiotics and (6) original 305
- articles. 306

312

319

320

- To broaden the search terms, asterisks were added to the end of the words. 307
- 308 Keywords were combined using the Boolean operators "AND", "OR" and "NOT". The
- 309 search strategy is detailed in Table 1.
- 310 The results of the different levels of the search can be found in the attached
- 311 supplementary files.

Inclusion criteria

- 313 Only original articles were selected. Biographies, commentaries, duplicate
- 314 publications, editorials, guides, interviews, news items, personal narratives, errata,
- 315 retractions, reviews, systematic reviews and meta-analyses were excluded. In the
- next level of screening, only articles published in English that had mechanistic results 316
- and outcomes, at least in vivo, were selected by analysis of the abstract. 317
- Publications that met the criteria above were downloaded and reviewed. 318

3. Results

3.1. Literature search

- 321 Figure 1 shows the flow diagram of the search and selection process. This diagram
- 322 has been made by adapting the work to the guidelines for systematic searches
- recommended by Preferred Reporting Items for Systematic Reviews and Meta-323
- Analyses (PRISMA). 114 The Pubmed search yielded 202 results. The articles were 324
- 325 screened for eligibility criteria. As a result of the first screening, a total of 108 articles

were selected. After applying the next filtering on the type of results, a total of 62 articles remained for analysis. Of these 62 studies, 15 included human clinical trials

328 (Fig. 1).

326 327

329

330 331

332

333

334

335 336

337

338

339

340

341 342

343

344

345

346

347

348 349

350

351

352

353 354

355

3.2. Characteristics of included results

Table 2 shows the characteristics of the included studies. The type of intervention performed, type of cancer, type of study, impact on the microbiota, the mechanism proposed by the authors, and its impact on cancer development are shown. Finally, the last column includes a more subjective criterion, namely the quality of the data analyzed on a scale ranging from very low = 1, low = 2, medium = 3, high = 4, very high = 5. This criterion has been assessed according to the experimental design, statistical analysis and strength of the mechanisms demonstrated. Figure 2 shows the distribution of the included studies.

4. Discussion

A patient's microbiota plays a key role in modulating the immune system as a natural defense against tumor development and during cancer treatment, especially in CRC.²⁰ However, there is no defined therapeutic strategy for the microbiota in a CRC patient. To make the transition from clinical trials to patient treatment, it is necessary to review all published data on microbiota-related therapeutic approaches in CRC in a systematic way. The therapeutic modulators of the microbiome include primarily probiotics, prebiotics, symbiotics and nutrition.

Probiotics

One of the most frequent probiotic combinations for the study of CRC is that of Lactobacillus and Bifidobacterium. In several studies, pre-inoculation with Lactobacillus acidophilus or a cocktail approved for commercial use in China, called Bifico, which consists of Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis, reduced colon tumor growth in preclinical models. 118, 169 Bifico treatment also caused a decrease in Desulfovibrio, Mucispirillum and Odoribacter, associated with an enrichment in Lactobacillus. 118 However, another study reported that a combination of Bifidobacterium and Lactobacillus was not able to improve 5-FU treatment, despite improving the flora composition. 123

357

358

359 360

361

362

363

364

365

366 367

368

369 370

371

372 373

374

375

376

377

378 379

380 381

382

383 384

385

386

387

388

The mixture of three different strains of Lactobacillus and one of Bifidobacterium decreases the incidence and number of tumors in a preclinical model of CRC associated with colitis. 130 VSL#3 is a commercial probiotic containing a mixture of different strains of Lactobacillus, Bifidobacterium and Streptococcus. In a murine model with a Western diet, treatment with VSL#3 and metformin decreases colonic tumor formation, through reduced cell proliferation and macrophage infiltration,. 128 However, VSL#3 alone shows no protection against colonic tumor development in other studies. 116, 128 In fact, in a model of colitis associated with CRC and inflammation, VSL#3 increases macroscopic lesions, as well as their invasiveness and histological grade. 116 Therefore, it is important not to prescribe probiotics without scientific basis. In addition, the Lactobacillus genus alone is probably the most widely tested probiotic in CRC (Fig. 2 d&e). A study conducted with Lactobacillus casei in a model of CRC associated with colitis, combined with FOLFOX, showed improvement in various inflammatory and microbiota parameters; however, it did not show reduction in tumor development. 124 In this study, FOLFOX increases apoptosis in intestinal epithelial cells, while the probiotic inhibits cell death in healthy epithelial cells. 124 Nonetheless, it is difficult to assess the effect of a given treatment in an animal model, but it is even more complicated in models that use injections of tumor cells in different (heterotopic) locations, as is the case in this study. 124 Another study with the L. casei BL23 strain showed a total inhibition of the incidence of colorectal tumors in mice. This mechanism could be associated with increased expression of Bik, a proapoptotic gene, and a decrease in Ki67. Lactobacillus reuteri strain can also reduce colon tumors through the production of histamine, which is associated with a decrease in inflammatory markers at both local and systemic levels. 127 Another well-studied probiotic is Akkermansia muciniphila (Fig. 2 d). Several studies support its potential use in CRC patients with promising results. Preclinical studies have shown that it is more efficient against CRC than IL-2 therapy. The combination of A. muciniphila and IL-2 was significantly more effective than their separate actions in reducing tumor volume and increasing survival. 115 The effect of A. muciniphila appears to be related to a membrane protein called Amuc, which is recognized by Toll-like receptor 2 (TLR2). Cellular mechanisms and immune effects mediated by TLR2 lead to increased efficacy of IL-2 immune therapy. 115

Therefore, it seems that probiotics, especially lactic acid bacteria, SCFA producers and A. muciniphila could be beneficial for patients diagnosed with CRC.

Prebiotics

389

390

391

392

393

394

395 396

397

398

399

400 401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

Many of the prebiotics used in the CRC literature are oligo- and polysaccharides (Fig. 2 e & f). Among them, pectin has shown beneficial effects such as SCFA production, 170 reduction of ammonia, 171 and improve glucose tolerance. 172 Pectin is the fundamental metabolite of plant walls, and its fermentation serves as a source of energy for numerous microorganisms, producing metabolites with beneficial functions for our organism. 131, 173 Furthermore, pectin is currently used in numerous food additives, so its study is of great interest. 131, 174 In fact, it has been observed that pectin can be beneficial against several types of tumors such as CRC, breast and prostate cancer by halting tumor development. 174 Its effect seems to be mediated through the increase of different SCFA-producing bacteria and in particular acetate, and the enhancement of the immune response through IFN-y-producing TCD8+. In addition, a transplantation of fecal microbiota from PD-1 refractory patients showed enhanced anti-tumor response in PD-1 and pectin-treated mice. 131 Galacto-oligosaccharides derived from lactulose, and mainly lactose, have been tested in preclinical models with promising results in terms of reducing tumor development and modulating the microbiota. 140 Other well-studied oligosaccharides include fructo-oligosaccharides/inulin and mucin. 66, 132, 164 Inulin has been shown to significantly reduce the volume of subcutaneously transplanted colon tumors, while mucin did not cause any significant change. 132 In another study, inulin was reported to strongly inhibit tumor development through modification of the microbiota and butyrate production. 66 This paper dissects the pathways leading to this effect, finding that butyrate is absorbed, but not oxidized due to the Warburg effect of cancer cells.¹⁷⁵ However, healthy colonocytes do use butyrate as a major source of energy. 176 In tumor cells, butyrate accumulates in the cell interior where it inhibits histone deacetylase activity, thus decreasing proliferation and increasing apoptosis.⁶⁶

Studies with compounds derived from citrus peel, such as polymethoxyflavones, have shown positive effects in preventing the development of CRC. However, mechanisms such as autophagy, which the authors highlight as possible effector pathways for these compounds, are poorly analyzed and higher quality studies are needed to draw valid conclusions. 142 Other prebiotics, such as green tea extract

424 425

426

427 428

429

430

431

432

433

434

435

436

437

438 439

440

441

442 443

444 445

446

447

448

449 450

451

452

453

454

(EGCG), have been shown to reduce colonic tumors, but these studies are of low scientific quality (grading = 1 and 2) for the reasons mentioned above. In a rat model of colitis-associated cancer using EGCG and resistant starch. EGCG was shown to have no effect. Only resistant starch was able to decrease colonic tumor formation through a change in the microbial flora, increasing SCFA production, and decreasing inflammation. 154 There is great interest among scientists in Asia, but particularly in China, in demonstrating the effects of different therapeutic approaches to traditional medicine through the microbiota. 135, 148 For example, the Canmei formula contains herbs called Mume sieb and Marci Hieronymi, whose more than 41 active ingredients include DLarginine, L-tyrosine, L(-)-carnitine, adenine, quanine or ambrosic acid. This formulation was shown to decrease the incidence of colonic tumors by reducing inflammation and improving dysbiosis. 137 Another study using a Boswellia serrata

resin extract has also demonstrated, in preclinical models, its ability to reduce colonic tumor formation. 144 Many of these studies present positive results for the inhibition of

CRC development. However, in general, they are of low quality (grading = 1 and 2) due to a lack of mechanistic and statistically robust data and therefore do not allow

for reliable conclusions to be drawn.

Symbiotics

One of the most interesting proposals in the literature is the possibility of using symbiotics as therapeutic options to increase the efficacy of available treatments. It has been observed that the use of C. butyricum, surrounded by dextran and bound to capecitabine or diclofenac, can increase the efficacy of these chemotherapeutics by >500%. This symbiotic decreases tumor invasiveness and also promotes a healthier and more diverse microbiota coupled with increased production of SCFA.96 This work is interesting for clinical studies as both dextran and C. butyricum are approved for use in food applications and showed no notable side effects. 96 Another symbiotic studied is the combination of Lactobacillus gasseri 505 and Cudrania tricuspidata leaf extract in fermented milk. This symbiotic was shown to reduce tumor incidence and malignancy in a model of CRC-associated colitis. 146 Therefore, the use of symbiotics for improving gut microbiota in patients with CRC

seems promising, although more studies are needed to clearly define which

symbiotic should be used, the dose, the timing, and in which specific CRC patients.

456

457

458

459 460

461

462

463

464

465

466

467

468

469 470

471

472 473

474

475

476

477

478

479 480

481 482

483

484

485 486

487

Healthy nutrition as a source of pre- and probiotics

Most, if not all pro-, pre- and symbiotics can be obtained naturally through a healthy diet. Prebiotics have been isolated from mushrooms, 138 fruits, 142, 151 dairy, 140 rice, 161 and green tea¹³⁸ and probiotics from fruit skins, 117 dairy, 122 and fermented products. 146 From infancy, a balanced, non-processed plant-based nutrition is the best way to have a proper gut microbiota. In fact, it has been shown that a diet high in soluble fiber is not able to reverse the erosion of intestinal mucus caused by a diet without fiber. However, the same diet, but high in intact plant fiber decreased mucus degradation, strengthening the intestinal barrier.⁶⁷ Anthocyanins, compounds with a positive impact on the health of patients with CRC, are present in many foods such as tea, coffee, cocoa and red fruits. 177 In this regard, it has been shown that anthocyanins in blackberries can reduce the incidence of CRC, through diminished local inflammation and improved microbiota. 151 Another food with interesting results is the marine extract of certain shellfish that may have anticarcinogenic effects. Using metabolomic analysis techniques, one can discern which compounds are toxic to tumor cells, opening the door to precision nutrition. 147, 178 Algae-derived products such as fucoxanthin, a carotenoid present in high levels in wakame (Undaria pinnatifida), have also shown to decrease the number of adenocarcinomas and total tumors. This effect was also associated with an increase in the number of Lachnospiraceae. 134 Spices have similarly attracted a great deal of interest for their health-promoting properties. For example, nutmeg can decrease the development of APC genetically engineered tumors by modulating the metabolism of the microbial flora and improving lipid metabolism. 150 Numerous food extracts are also used in traditional Chinese medicine, including American ginseng. The use of this compound in a murine model prevented tumors and ameliorated dysbiosis induced by different murine models of CRC and high-fat diet. 153, 155 Moving from specific foods to dietary patterns, the Mediterranean diet has been shown to have beneficial effects on multiple levels, specifically in the prevention of certain types of cancer. 179 In the case of CRC, epidemiological studies show that adherence to a Mediterranean diet reduces the incidence of CRC by up to 11%. 180 Likewise, the effect of mixing a Mediterranean diet with other types of diet (low-fat or high-fat Western-type diet) has been studied in models of cancer associated with

489

490

491

492 493

494

495

496

497

498 499

500

501

502

503 504

505

506

507

508 509

510

511

512

513

514 515

516

517

518 519

520

colitis. This study showed that consumption of the Mediterranean diet, regardless of the diet with which it was mixed, decreased tumor incidence, and improved the microbiota, especially when accompanying a high-fat diet. 149

At the highest level of scientific evidence are randomized clinical trials. Within this

Randomized clinical trials

group, those conducted with lactic acid strains stand out. Among them, a study conducted with 78 patients analyzed the role of probiotics in reducing side effects after CRC surgery. Inclusion criteria were a diagnosis of stage III adenomatous CRC and that the patients were to undergo surgery. The probiotic group received postoperative treatment with a mixture of different strains of Lactobacillus, Bifidobacterium, and Streptococcus thermophilus for almost one year. The most important conclusion of this study was that probiotic treatment decreased the most frequent side effects of surgery, specifically paralytic ileus. However, limitations of this study include the low number of subjects included, the apparent lack of doubleblinding, active placebo, and a weak statistical analysis.⁷⁴ In another clinical trial, a probiotic consisting of Bifidobacterium longum, Lactobacillus acidophilus and Enterococcus faecalis was tested in CRC patients undergoing surgery. It was shown that, in addition to improving the diversity of the microbial flora, the probiotic mixture was able to decrease the levels of Fusobacterium, a bacterium associated with the development of CRC, by >500%. 156 In addition, its use decreased post-operative infections.¹⁵⁷ Another similar probiotic mixture consisting of *Lactobacillus plantarum*, Lactobacillus acidophilus and Bifidobacterium longum reduced the risk of postoperative infection and improved the intestinal epithelial barrier, resulting in a lower incidence of diarrhea, abdominal pain, and fever, 159 A study using a mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) showed that only the latter (La1) colonized the gut, reducing the number of pathogenic microorganisms and reducing colonic inflammation in CRC patients undergoing surgery. This result shows that adding more probiotics will not have a greater effect and it is important to study each strain individually and its combination before it can be recommended to patients. 160 In another clinical trial, a probiotic mixture consisting of Enterococcus, Clostridium and Bacillus was used in patients undergoing CRC surgery to discern whether their consumption could ameliorate the adverse effects of surgery. It was found that peri-

522

523 524

525

526

527

528

529

530 531

532

533

534

535

536

537 538

539

540

541 542

543

544

545

546

547

548 549

550

551

552

553 554 surgical use of this mixture significantly reduced incisional infections and decreased the acute inflammatory response to surgery. 158 However, in this study, no randomization was performed, and patients were included in one group (control) or the other (probiotic) according to the date of surgery, with the control group (2009-2011) prior to the probiotic group (2011-2013). This does not allow for a clear conclusion on the effect of the probiotic, because multiple factors may have changed during those two years, including greater experience of the surgical team or better technical means. In this regard, the authors describe that a higher number of laparotomies were performed in the probiotic group, and that performing or not performing laparotomy is a key factor related to the outcome of the surgery. 158 As far as prebiotics are concerned, rice bran is of great interest due to its large commercial use. Numerous studies show the benefit of whole grain consumption in the prevention of CRC.¹⁸¹ In the case of rice bran, various phytochemicals in its composition have been associated with a decrease in the risk of cancer development, in particular CRC. 182 Its consumption increases levels of *Firmicutes* and Lactobacillus¹⁶¹ and produces numerous metabolic modifications that could be related to a decrease in the risk of developing CRC. 166 In another clinical trial with prebiotics in CRC patients, a mixture of different nondigestible oligosaccharides was used for 7 days before patients underwent radical surgery to remove the tumor. Both groups received the same nutrition (provided by the hospital) in the 7 days before and after surgery (parenteral nutrition). Surgery decreased the diversity of the microbiota in both groups, underlining the impact of these interventions on gut health. Interestingly, a principal component analysis of microbiome diversity was able to unequivocally identify samples from postoperative patients who had received prebiotics. Furthermore, the use of these prebiotics improved systemic immune function, confirming the positive effect that microbiota can have on immune response. An important limitation of this study is that the randomization did not specify the stage or type of tumor. 162 Symbiotics have also been tested in randomized clinical trials. A commercially named symbiotic, simbioflora®, containing fructooligosaccharides, 3 strains of Lactobacillus, and Bifidobacterium lactis showed promising results in CRC patients undergoing surgery. The use of this symbiotic significantly reduced inflammation and postoperative infections. 163 However, this is a small study of patients with cancer at

different stages, so the data should be analyzed with caution. In another study, a

557 558

559

560 561

562

563

564 565

566

567

568 569

570

571 572

573

574

585

586

mixture of Bifidobacterium, Lactobacillus and inulin strains was used in stage I-III patients undergoing surgery. This treatment resulted in an improvement in the composition of the microbial community, especially the SCFA-producing bacterium. However, this study does not define blind randomization of patients and there is no placebo, so the data should be also analyzed with caution. 164 Finally, a randomized clinical study was conducted in 20 healthy subjects with backcrossed arms with the aim of preventing CRC. This study of 4 weeks duration per intervention (switching every 4 weeks to another arm until each group completed all 4) was done with 4 different arms: placebo, Bifidobacterium lactis, resistant starch and their combination (Bifidobacterium lactis and resistant starch). It was shown that in healthy subjects the combination of Bifidobacterium lactis and resistant starch increased the levels of Lachnospiraceae spp. However, the other parameters analyzed, such as stool mass, pH or ammonium, SCFA, circulating cytokines, and markers of colonic epithelial health, did not change. 165 The use of pomegranate extract in patients undergoing surgical tumor resection has also been investigated. Pomegranate extract was shown to produce significant changes in the expression of numerous genes and microRNAs related to tumor development. These results underline the crucial role of diet in modifying gene

5. Conclusion

575 We can summarize the conclusions of this work regarding the modification of the microbiota in the CRC patient as follows: 576

expression and, therefore, in the etiology of disease. 167, 168

- 1) Antibiotic use is one of the major deleterious factors for the prognosis of 577 treatment efficacy, due to its harmful effect on the microbiota. 578
- 579 2) **Prebiotics** such as inulin and resistant starch can support the development of a 580 healthy microbiota.
- 581 3) Probiotics, mainly based on SCFA-producing lactic acid strains, show a 582 favorable profile in preclinical and clinical studies. However, not all strains are equally favorable and are therefore not recommended for use in patients without 583 individualized study of the patient and the probiotic. 584
 - 4) A healthy and varied nutrition, consisting mainly of unprocessed plant-based foods, seems to be one of the best sources to maintain a homeostatic microbiota.

588

589

590 591

592

593

594

595

596

597

598

599

600

601

602 603

604

605

606

607

608

609

610

611

612

613

614

615

Finally, after a detailed analysis of the literature, in a **healthy person**, there is no need to recommend the use of pre-, pro- or symbiotics in addition to a healthy diet. However, CRC patients often have severe dysbiosis due to their own disease, and broad-spectrum antibiotic use. In these patients, apart from a healthy diet, or if a healthy diet cannot be established, carefully chosen pre-, pro- and/or symbiotics may be beneficial to restore a beneficial microbiota and support the efficacy of hospital treatments more effectively. **Acknowledgements** We thank Dr. Alberto Canfran-Duque and Noemi Rotllan for their for critical reading of the manuscript. We apologize to those whose work could not be cited owing to space limitations. **Authors Contributions** JMM designed and performed the systematic search, wrote and edited the manuscript. SBE contributed to the editing and interpretation of the manuscript. All authors read and edited the final draft of the manuscript. **Competing Financial Interest** The authors declare no conflicts of interest Correspondence and requests for materials should be addressed to: madrigalmatute@ibions.com. Data availability There are not restrictions on data availability in this manuscript.

617

6. Bibliography

- 1. Henrikson, N.B. et al. Family history and the natural history of colorectal 618
- cancer: systematic review. Genet Med 17, 702-712 (2015). 619
- 620 2. Czene, K., Lichtenstein, P. & Hemminki, K. Environmental and heritable
- causes of cancer among 9.6 million individuals in the Swedish Family-Cancer 621
- 622 Database. Int J Cancer 99, 260-266 (2002).
- 623 Lichtenstein, P. et al. Environmental and heritable factors in the causation of
- 624 cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J
- 625 Med 343, 78-85 (2000).
- 626 4. Jiao, S. et al. Estimating the heritability of colorectal cancer. Hum Mol Genet
- **23**, 3898-3905 (2014). 627
- 628 5. Syngal, S. et al. ACG clinical guideline: Genetic testing and management of
- 629 hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110, 223-262; quiz
- 630 263 (2015).
- 6. Dekker, E., Tanis, P.J., Vleugels, J.L.A., Kasi, P.M. & Wallace, M.B. Colorectal 631
- 632 cancer. Lancet **394**, 1467-1480 (2019).
- 633 7. Nishida, A. et al. Gut microbiota in the pathogenesis of inflammatory bowel
- disease. Clin J Gastroenterol 11, 1-10 (2018). 634
- 635 Murphy, N. et al. Lifestyle and dietary environmental factors in colorectal
- 636 cancer susceptibility. Mol Aspects Med 69, 2-9 (2019).
- Crosnier, C., Stamataki, D. & Lewis, J. Organizing cell renewal in the intestine: 637
- stem cells, signals and combinatorial control. Nat Rev Genet 7, 349-359 (2006). 638
- 639 (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
- 640 Lyon (FR): International Agency for Research on Cancer; 2010. (IARC Monographs
- 641 on the Evaluation of Carcinogenic Risks to Humans, No. 92.); 2010).
- Mottram, D.S., Wedzicha, B.L. & Dodson, A.T. Acrylamide is formed in the 642
- Maillard reaction. *Nature* **419**, 448-449 (2002). 643
- (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 644 12.
- Chemical Agents and Related Occupations. Lyon (FR): International Agency for 645
- 646 Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic
- 647 Risks to Humans, No. 100F.) 2012).

- Diggs, D.L. et al. Polycyclic aromatic hydrocarbons and digestive tract 648
- 649 cancers: a perspective. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 29,
- 650 324-357 (2011).
- 14. Tabatabaei, S.M., Heyworth, J.S., Knuiman, M.W. & Fritschi, L. Dietary 651
- benzo[a]pyrene intake from meat and the risk of colorectal cancer. Cancer Epidemiol 652
- Biomarkers Prev 19, 3182-3184 (2010). 653
- 15. Coussens, L.M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 654
- 655 (2002).
- 656 16. Medema, J.P. Cancer stem cells: the challenges ahead. Nat Cell Biol 15, 338-
- 657 344 (2013).
- 658 17. Cancer Genome Atlas, N. Comprehensive molecular characterization of
- 659 human colon and rectal cancer. *Nature* **487**, 330-337 (2012).
- 660 18. Stappenbeck, T.S. & Virgin, H.W. Accounting for reciprocal host-microbiome
- interactions in experimental science. *Nature* **534**, 191-199 (2016). 661
- 662 19. Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G. & Gajewski, T.F. The microbiome
- 663 in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science 359,
- 664 1366-1370 (2018).
- 665 20. Thursby, E. & Juge, N. Introduction to the human gut microbiota. Biochem J
- 666 **474**, 1823-1836 (2017).
- 21. Claesson, M.J. et al. Gut microbiota composition correlates with diet and 667
- health in the elderly. Nature 488, 178-184 (2012). 668
- 22. Wang, T. et al. Structural segregation of gut microbiota between colorectal 669
- cancer patients and healthy volunteers. ISME J 6, 320-329 (2012). 670
- 671 23. Lin, Y. et al. NMR-based fecal metabolomics fingerprinting as predictors of
- 672 earlier diagnosis in patients with colorectal cancer. Oncotarget 7, 29454-29464
- (2016).673
- 24. Chen, J. & Vitetta, L. Inflammation-Modulating Effect of Butyrate in the 674
- Prevention of Colon Cancer by Dietary Fiber. Clin Colorectal Cancer 17, e541-e544 675
- 676 (2018).
- 25. Zeng, H., Safratowich, B.D., Wang, T.T.Y., Hamlin, S.K. & Johnson, L.K. 677
- 678 Butyrate Inhibits Deoxycholic-Acid-Resistant Colonic Cell Proliferation via Cell Cycle
- 679 Arrest and Apoptosis: A Potential Pathway Linking Dietary Fiber to Cancer
- 680 Prevention. *Mol Nutr Food Res* **64**, e1901014 (2020).

- 681 26. Tan, J. et al. The role of short-chain fatty acids in health and disease. Adv
- 682 Immunol 121, 91-119 (2014).
- 27. Ganapathy, V., Thangaraju, M., Prasad, P.D., Martin, P.M. & Singh, N. 683
- 684 Transporters and receptors for short-chain fatty acids as the molecular link between
- 685 colonic bacteria and the host. Curr Opin Pharmacol 13, 869-874 (2013).
- 28. Zhao, Y. et al. GPR43 mediates microbiota metabolite SCFA regulation of 686
- 687 antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR
- 688 and STAT3. Mucosal Immunol 11, 752-762 (2018).
- 689 29. Madara, J.L. & Pappenheimer, J.R. Structural basis for physiological
- 690 regulation of paracellular pathways in intestinal epithelia. J Membr Biol 100, 149-164
- 691 (1987).
- 692 30. Eeckhaut, V. et al. Butyricicoccus pullicaecorum in inflammatory bowel
- 693 disease. Gut 62, 1745-1752 (2013).
- 31. Kang, S. et al. Dysbiosis of fecal microbiota in Crohn's disease patients as 694
- 695 revealed by a custom phylogenetic microarray. Inflamm Bowel Dis 16, 2034-2042
- 696 (2010).
- 697 32. Takaishi, H. et al. Imbalance in intestinal microflora constitution could be
- 698 involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 298,
- 699 463-472 (2008).
- 700 33. Karlsson, C.L. et al. The microbiota of the gut in preschool children with
- normal and excessive body weight. Obesity (Silver Spring) 20, 2257-2261 (2012). 701
- 702 34. Crovesy, L., Masterson, D. & Rosado, E.L. Profile of the gut microbiota of
- adults with obesity: a systematic review. Eur J Clin Nutr 74, 1251-1262 (2020). 703
- 704 35. Vigsnaes, L.K., Brynskov, J., Steenholdt, C., Wilcks, A. & Licht, T.R. Gram-
- 705 negative bacteria account for main differences between faecal microbiota from
- 706 patients with ulcerative colitis and healthy controls. Benef Microbes 3, 287-297
- 707 (2012).
- 36. Wang, L. et al. A purified membrane protein from Akkermansia muciniphila or 708
- 709 the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of
- CD8(+) T cells in mice. Gut 69, 1988-1997 (2020). 710
- 37. Ottman, N. et al. Genome-Scale Model and Omics Analysis of Metabolic 711
- Capacities of Akkermansia muciniphila Reveal a Preferential Mucin-Degrading 712
- 713 Lifestyle. *Appl Environ Microbiol* **83** (2017).

- 38. Wang, G. *et al.* Role of SCFAs in gut microbiome and glycolysis for colorectal
- cancer therapy. *J Cell Physiol* **234**, 17023-17049 (2019).
- 716 39. Petersen, C. & Round, J.L. Defining dysbiosis and its influence on host
- 717 immunity and disease. *Cell Microbiol* **16**, 1024-1033 (2014).
- 40. Wong, S.H. & Yu, J. Gut microbiota in colorectal cancer: mechanisms of action
- and clinical applications. Nat Rev Gastroenterol Hepatol 16, 690-704 (2019).
- 720 41. Peters, B.A. et al. The gut microbiota in conventional and serrated precursors
- of colorectal cancer. *Microbiome* **4**, 69 (2016).
- 42. Dethlefsen, L., Huse, S., Sogin, M.L. & Relman, D.A. The pervasive effects of
- an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA
- 724 sequencing. *PLoS Biol* **6**, e280 (2008).
- 725 43. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates
- progression of NAFLD and obesity. *Nature* **482**, 179-185 (2012).
- 727 44. Newton, D.F., Cummings, J.H., Macfarlane, S. & Macfarlane, G.T. Growth of a
- 728 human intestinal Desulfovibrio desulfuricans in continuous cultures containing
- defined populations of saccharolytic and amino acid fermenting bacteria. J Appl
- 730 *Microbiol* **85**, 372-380 (1998).
- 45. Carbonero, F., Benefiel, A.C. & Gaskins, H.R. Contributions of the microbial
- hydrogen economy to colonic homeostasis. Nat Rev Gastroenterol Hepatol 9, 504-
- 733 518 (2012).
- 46. Roediger, W.E., Duncan, A., Kapaniris, O. & Millard, S. Reducing sulfur
- compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis.
- 736 Gastroenterology **104**, 802-809 (1993).
- 47. Suarez, F., Furne, J., Springfield, J. & Levitt, M. Production and elimination of
- sulfur-containing gases in the rat colon. *Am J Physiol* **274**, G727-733 (1998).
- 48. Cai, W.J., Wang, M.J., Ju, L.H., Wang, C. & Zhu, Y.C. Hydrogen sulfide
- induces human colon cancer cell proliferation: role of Akt, ERK and p21. Cell Biol Int
- 741 **34**, 565-572 (2010).
- 49. Deplancke, B. & Gaskins, H.R. Hydrogen sulfide induces serum-independent
- cell cycle entry in nontransformed rat intestinal epithelial cells. FASEB J 17, 1310-
- 744 1312 (2003).
- 50. Attene-Ramos, M.S., Wagner, E.D., Plewa, M.J. & Gaskins, H.R. Evidence
- that hydrogen sulfide is a genotoxic agent. *Mol Cancer Res* **4**, 9-14 (2006).

- Kanazawa, K. et al. Factors influencing the development of sigmoid colon 747
- cancer. Bacteriologic and biochemical studies. Cancer 77, 1701-1706 (1996). 748
- 52. Kostic, A.D. et al. Genomic analysis identifies association of Fusobacterium 749
- 750 with colorectal carcinoma. Genome Res 22, 292-298 (2012).
- 751 53. Castellarin, M. et al. Fusobacterium nucleatum infection is prevalent in human
- 752 colorectal carcinoma. Genome Res 22, 299-306 (2012).
- 753 54. Yang, Y. et al. Fusobacterium nucleatum Increases Proliferation of Colorectal
- 754 Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4
- 755 Signaling to Nuclear Factor-kappaB, and Up-regulating Expression of MicroRNA-21.
- Gastroenterology 152, 851-866 e824 (2017). 756
- 757 55. Yu, T. et al. Fusobacterium nucleatum Promotes Chemoresistance to
- Colorectal Cancer by Modulating Autophagy. Cell 170, 548-563 e516 (2017). 758
- 759 56. Campisciano, G. et al. The Obesity-Related Gut Bacterial and Viral Dysbiosis
- Can Impact the Risk of Colon Cancer Development. *Microorganisms* 8 (2020). 760
- 761 57. Feng, Q. et al. Gut microbiome development along the colorectal adenoma-
- 762 carcinoma sequence. *Nat Commun* **6**, 6528 (2015).
- 763 58. Arthur, J.C. et al. Intestinal inflammation targets cancer-inducing activity of the
- 764 microbiota. Science 338, 120-123 (2012).
- 765 59. Garrett, W.S. The gut microbiota and colon cancer. Science 364, 1133-1135
- 766 (2019).
- 60. Dejea, C.M. et al. Patients with familial adenomatous polyposis harbor colonic 767
- biofilms containing tumorigenic bacteria. Science **359**, 592-597 (2018). 768
- 769 61. Zhang, G., Svenungsson, B., Karnell, A. & Weintraub, A. Prevalence of
- 770 enterotoxigenic Bacteroides fragilis in adult patients with diarrhea and healthy
- 771 controls. Clin Infect Dis 29, 590-594 (1999).
- 62. Turnbaugh, P.J. et al. A core gut microbiome in obese and lean twins. Nature 772
- 773 **457**, 480-484 (2009).
- 63. Turnbaugh, P.J. et al. The effect of diet on the human gut microbiome: a 774
- 775 metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1, 6ra14
- 776 (2009).
- 64. Carmody, R.N. et al. Diet dominates host genotype in shaping the murine gut 777
- microbiota. Cell Host Microbe 17, 72-84 (2015). 778
- 779 65. De Filippis, F. et al. High-level adherence to a Mediterranean diet beneficially
- 780 impacts the gut microbiota and associated metabolome. Gut 65, 1812-1821 (2016).

- Donohoe, D.R. et al. A gnotobiotic mouse model demonstrates that dietary 781
- 782 fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-
- 783 dependent manner. Cancer Discov 4, 1387-1397 (2014).
- 784 67. Desai, M.S. et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the
- Colonic Mucus Barrier and Enhances Pathogen Susceptibility. Cell 167, 1339-1353 785
- 786 e1321 (2016).
- 787 68. Halmos, E.P., Power, V.A., Shepherd, S.J., Gibson, P.R. & Muir, J.G. A diet
- 788 low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology
- 789 **146**, 67-75 e65 (2014).
- 69. Sanders, M.E., Merenstein, D.J., Reid, G., Gibson, G.R. & Rastall, R.A. 790
- 791 Probiotics and prebiotics in intestinal health and disease: from biology to the clinic.
- 792 Nat Rev Gastroenterol Hepatol 16, 605-616 (2019).
- 793 70. Nami, Y., Haghshenas, B., Haghshenas, M., Abdullah, N. & Yari
- Khosroushahi, A. The Prophylactic Effect of Probiotic Enterococcus lactis IW5 794
- 795 against Different Human Cancer Cells. Front Microbiol 6, 1317 (2015).
- 796 71. Kaeid Sharaf, L. & Shukla, G. Probiotics (Lactobacillus acidophilus and
- 797 Lactobacillus rhamnosus GG) in Conjunction with Celecoxib (selective COX-2
- 798 inhibitor) Modulated DMH-Induced Early Experimental Colon Carcinogenesis. Nutr
- 799 Cancer 70, 946-955 (2018).
- 72. Sharaf, L.K., Sharma, M., Chandel, D. & Shukla, G. Prophylactic intervention 800
- 801 of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated
- 802 apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. BMC
- 803 Cancer 18, 1111 (2018).
- 804 73. Li, J. et al. Probiotics modulated gut microbiota suppresses hepatocellular
- 805 carcinoma growth in mice. Proc Natl Acad Sci U S A 113, E1306-1315 (2016).
- 806 74. Bajramagic, S. et al. Usage of Probiotics and its Clinical Significance at
- Surgically Treated Patients Sufferig from Colorectal Carcinoma. Med Arch 73, 316-807
- 320 (2019). 808
- 809 75. Azcarate-Peril, M.A., Sikes, M. & Bruno-Barcena, J.M. The intestinal
- microbiota, gastrointestinal environment and colorectal cancer: a putative role for 810
- 811 probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol
- 812 **301**, G401-424 (2011).

- 76. Zhuo, Q. et al. Lysates of Lactobacillus acidophilus combined with CTLA-4-813
- 814 blocking antibodies enhance antitumor immunity in a mouse colon cancer model. Sci
- 815 Rep 9, 20128 (2019).
- 77. Eeckhaut, V. et al. The Probiotic Butyricicoccus pullicaecorum Reduces Feed 816
- 817 Conversion and Protects from Potentially Harmful Intestinal Microorganisms and
- 818 Necrotic Enteritis in Broilers. *Front Microbiol* **7**, 1416 (2016).
- 819 78. Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal
- 820 epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110, 9066-9071
- 821 (2013).
- 79. Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 822
- 823 immunotherapy in melanoma patients. Science **359**, 97-103 (2018).
- 824 80. Routy, B. et al. Gut microbiome influences efficacy of PD-1-based
- 825 immunotherapy against epithelial tumors. Science **359**, 91-97 (2018).
- 81. Zhai, R. et al. Strain-Specific Anti-inflammatory Properties of Two 826
- 827 Akkermansia muciniphila Strains on Chronic Colitis in Mice. Front Cell Infect
- 828 Microbiol 9, 239 (2019).
- 82. Paolillo, R., Romano Carratelli, C., Sorrentino, S., Mazzola, N. & Rizzo, A. 829
- 830 Immunomodulatory effects of Lactobacillus plantarum on human colon cancer cells.
- 831 Int Immunopharmacol 9, 1265-1271 (2009).
- 83. Kahouli, I., Malhotra, M., Westfall, S., Alaoui-Jamali, M.A. & Prakash, S. 832
- 833 Design and validation of an orally administrated active L. fermentum-L. acidophilus
- 834 probiotic formulation using colorectal cancer Apc (Min/+) mouse model. Appl
- 835 Microbiol Biotechnol 101, 1999-2019 (2017).
- 836 84. Zhu, J. et al. Lactobacillus salivarius Ren prevent the early colorectal
- carcinogenesis in 1, 2-dimethylhydrazine-induced rat model. J Appl Microbiol 117, 837
- 838 208-216 (2014).
- 85. Chen, L. et al. NLRP12 attenuates colon inflammation by maintaining colonic 839
- microbial diversity and promoting protective commensal bacterial growth. Nat 840
- 841 Immunol 18, 541-551 (2017).
- 86. Redman, M.G., Ward, E.J. & Phillips, R.S. The efficacy and safety of 842
- 843 probiotics in people with cancer: a systematic review. Ann Oncol 25, 1919-1929
- 844 (2014).
- 845 87. Gibson, G.R. et al. Expert consensus document: The International Scientific
- 846 Association for Probiotics and Prebiotics (ISAPP) consensus statement on the

- definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 14, 491-502 847
- 848 (2017).
- 88. van Loo, J., Coussement, P., de Leenheer, L., Hoebregs, H. & Smits, G. On 849
- 850 the presence of inulin and oligofructose as natural ingredients in the western diet. Crit
- 851 Rev Food Sci Nutr 35, 525-552 (1995).
- 852 89. Roberfroid, M.B., Van Loo, J.A. & Gibson, G.R. The bifidogenic nature of
- chicory inulin and its hydrolysis products. *J Nutr* **128**, 11-19 (1998). 853
- 854 90. Campbell, J.M., Fahey, G.C., Jr. & Wolf, B.W. Selected indigestible
- 855 oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH
- 856 and microflora in rats. J Nutr 127, 130-136 (1997).
- 857 91. Fehlbaum, S. et al. In Vitro Fermentation of Selected Prebiotics and Their
- Effects on the Composition and Activity of the Adult Gut Microbiota. Int J Mol Sci 19 858
- 859 (2018).
- 92. Li, K. et al. Dietary inulin alleviates diverse stages of type 2 diabetes mellitus 860
- 861 via anti-inflammation and modulating gut microbiota in db/db mice. Food Funct 10,
- 862 1915-1927 (2019).
- 863 93. Fuentes-Zaragoza, E. et al. Resistant starch as prebiotic: A review. Starch -
- 864 Stärke **63**, 406-415 (2011).
- 865 Sharma, A., Yadav, B.S. & Ritika Resistant Starch: Physiological Roles and
- Food Applications. Food Reviews International **24**, 193-234 (2008). 866
- 867 95. Farai, A., Vasanthan, T. & Hoover, R. The effect of extrusion cooking on
- 868 resistant starch formation in waxy and regular barley flours. Food Research
- 869 International **37**, 517-525 (2004).
- 870 96. Zheng, D.W. et al. Prebiotics-Encapsulated Probiotic Spores Regulate Gut
- 871 Microbiota and Suppress Colon Cancer. Adv Mater 32, e2004529 (2020).
- 872 97. Swanson, K.S. et al. The International Scientific Association for Probiotics and
- 873 Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics.
- 874 Nat Rev Gastroenterol Hepatol 17, 687-701 (2020).
- 875 98. Le Leu, R.K., Hu, Y., Brown, I.L., Woodman, R.J. & Young, G.P. Synbiotic
- 876 intervention of Bifidobacterium lactis and resistant starch protects against colorectal
- 877 cancer development in rats. Carcinogenesis 31, 246-251 (2010).
- 878 99. Ganesh, K. et al. Immunotherapy in colorectal cancer: rationale, challenges
- 879 and potential. Nat Rev Gastroenterol Hepatol 16, 361-375 (2019).

- 100. Paulos, C.M. et al. Microbial translocation augments the function of adoptively 880
- transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 117, 881
- 882 2197-2204 (2007).
- 883 101. lida, N. et al. Commensal bacteria control cancer response to therapy by
- modulating the tumor microenvironment. Science **342**, 967-970 (2013). 884
- 885 102. Viaud, S. et al. The intestinal microbiota modulates the anticancer immune
- 886 effects of cyclophosphamide. Science **342**, 971-976 (2013).
- 887 103. Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the
- 888 gut microbiota. *Science* **350**, 1079-1084 (2015).
- 104. Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and 889
- 890 facilitates anti-PD-L1 efficacy. Science **350**, 1084-1089 (2015).
- 891 105. Gaines, S. et al. Western Diet Promotes Intestinal Colonization by
- 892 Collagenolytic Microbes and Promotes Tumor Formation After Colorectal Surgery.
- 893 Gastroenterology 158, 958-970 e952 (2020).
- 894 106. Chen, D.S. & Mellman, I. Elements of cancer immunity and the cancer-
- 895 immune set point. *Nature* **541**, 321-330 (2017).
- 896 107. Matson, V. et al. The commensal microbiome is associated with anti-PD-1
- 897 efficacy in metastatic melanoma patients. Science **359**, 104-108 (2018).
- 108. Alberda, W.J. et al. The Importance of a Minimal Tumor-Free Resection 898
- Margin in Locally Recurrent Rectal Cancer. *Dis Colon Rectum* **58**, 677-685 (2015). 899
- 900 109. Manfredi, S. et al. Incidence and patterns of recurrence after resection for cure
- 901 of colonic cancer in a well defined population. Br J Surg 93, 1115-1122 (2006).
- 902 110. Naxerova, K. et al. Origins of lymphatic and distant metastases in human
- 903 colorectal cancer. *Science* **357**, 55-60 (2017).
- 904 111. Fermor, B., Umpleby, H.C., Lever, J.V., Symes, M.O. & Williamson, R.C.
- 905 Proliferative and metastatic potential of exfoliated colorectal cancer cells. J Natl
- 906 Cancer Inst **76**, 347-349 (1986).
- 112. Shogan, B.D. et al. Collagen degradation and MMP9 activation by 907
- 908 Enterococcus faecalis contribute to intestinal anastomotic leak. Sci Transl Med 7,
- 286ra268 (2015). 909
- 910 113. Mirnezami, A. et al. Increased local recurrence and reduced survival from
- colorectal cancer following anastomotic leak: systematic review and meta-analysis. 911
- 912 Ann Surg **253**, 890-899 (2011).

- 114. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. & Group, P. Preferred 913
- 914 reporting items for systematic reviews and meta-analyses: the PRISMA statement.
- 915 PLoS Med 6, e1000097 (2009).
- 115. Shi, L. et al. Combining IL-2-based immunotherapy with commensal probiotics 916
- 917 produces enhanced antitumor immune response and tumor clearance. J Immunother
- 918 Cancer 8 (2020).
- 919 116. Arthur, J.C. et al. VSL#3 probiotic modifies mucosal microbial composition but
- 920 does not reduce colitis-associated colorectal cancer. Sci Rep 3, 2868 (2013).
- 921 117. Chandel, D., Sharma, M., Chawla, V., Sachdeva, N. & Shukla, G. Isolation,
- characterization and identification of antigenotoxic and anticancerous indigenous 922
- 923 probiotics and their prophylactic potential in experimental colon carcinogenesis. Sci
- 924 Rep **9**, 14769 (2019).
- 925 118. Song, H. et al. Pretreatment with probiotic Bifico ameliorates colitis-associated
- cancer in mice: Transcriptome and gut flora profiling. Cancer Sci 109, 666-677 926
- 927 (2018).
- 928 119. Xu, H. et al. Inhibitory Effects of Breast Milk-Derived Lactobacillus rhamnosus
- 929 Probio-M9 on Colitis-Associated Carcinogenesis by Restoration of the Gut Microbiota
- 930 in a Mouse Model. *Nutrients* **13** (2021).
- 931 120. Chang, S.C. et al. A gut butyrate-producing bacterium Butyricicoccus
- pullicaecorum regulates short-chain fatty acid transporter and receptor to reduce the 932
- progression of 1,2-dimethylhydrazine-associated colorectal cancer. Oncol Lett 20, 933
- 934 327 (2020).
- 121. Hradicka, P., Beal, J., Kassayova, M., Foey, A. & Demeckova, V. A Novel 935
- 936 Lactic Acid Bacteria Mixture: Macrophage-Targeted Prophylactic Intervention in
- 937 Colorectal Cancer Management. *Microorganisms* **8** (2020).
- 122. Silveira, D.S.C. et al. Lactobacillus bulgaricus inhibits colitis-associated cancer 938
- 939 via a negative regulation of intestinal inflammation in azoxymethane/dextran sodium
- 940 sulfate model. World J Gastroenterol 26, 6782-6794 (2020).
- 941 123. Yuan, L. et al. The influence of gut microbiota dysbiosis to the efficacy of 5-
- 942 Fluorouracil treatment on colorectal cancer. Biomed Pharmacother 108, 184-193
- 943 (2018).
- 944 124. Chang, C.W. et al. Lactobacillus casei Variety rhamnosus Probiotic
- 945 Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a
- 946 Syngeneic Colorectal Cancer Model. Front Microbiol 9, 983 (2018).

- 947 125. Bindels, L.B. et al. Increased gut permeability in cancer cachexia: mechanisms
- 948 and clinical relevance. Oncotarget 9, 18224-18238 (2018).
- 949 126. Jacouton, E., Chain, F., Sokol, H., Langella, P. & Bermudez-Humaran, L.G.
- 950 Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal
- Cancer. Front Immunol 8, 1553 (2017). 951
- 127. Gao, C. et al. Gut Microbe-Mediated Suppression of Inflammation-Associated 952
- Colon Carcinogenesis by Luminal Histamine Production. Am J Pathol 187, 2323-953
- 954 2336 (2017).
- 955 128. Chung, E.J. et al. Combination of metformin and VSL#3 additively suppresses
- 956 western-style diet induced colon cancer in mice. Eur J Pharmacol 794, 1-7 (2017).
- 957 129. da Silva Duarte, V. et al. Chemoprevention of DMH-Induced Early Colon
- Carcinogenesis in Male BALB/c Mice by Administration of Lactobacillus Paracasei 958
- 959 DTA81. Microorganisms 8 (2020).
- 130. Mendes, M.C.S. et al. Microbiota modification by probiotic supplementation 960
- 961 reduces colitis associated colon cancer in mice. World J Gastroenterol 24, 1995-
- 962 2008 (2018).
- 131. Zhang, S.L. et al. Pectin supplement significantly enhanced the anti-PD-1 963
- 964 efficacy in tumor-bearing mice humanized with gut microbiota from patients with
- 965 colorectal cancer. Theranostics 11, 4155-4170 (2021).
- 132. Li, Y. et al. Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth. 966
- Cell Rep 30, 1753-1766 e1756 (2020). 967
- 133. Zhu, L.Q. et al. Evodiamine inhibits high-fat diet-induced colitis-associated 968
- cancer in mice through regulating the gut microbiota. J Integr Med 19, 56-65 (2021). 969
- 970 134. Terasaki, M. et al. Alteration of fecal microbiota by fucoxanthin results in
- 971 prevention of colorectal cancer in AOM/DSS-treated mice. Carcinogenesis (2020).
- 972 135. Luo, L. et al. The effect of menthol supplement diet on colitis-induced colon
- 973 tumorigenesis and intestinal microbiota. Am J Transl Res 13, 38-56 (2021).
- 974 136. Liu, X., Wang, L., Jing, N., Jiang, G. & Liu, Z. Biostimulating Gut Microbiome
- 975 with Bilberry Anthocyanin Combo to Enhance Anti-PD-L1 Efficiency against Murine
- 976 Colon Cancer. Microorganisms 8 (2020).
- 137. Zhang, H., Hui, D., Li, Y., Xiong, G. & Fu, X. Canmei Formula Reduces Colitis-977
- 978 Associated Colorectal Carcinogenesis in Mice by Modulating the Composition of Gut
- 979 Microbiota. *Front Oncol* **9**, 1149 (2019).

- 980 138. Khan, I. et al. Mushroom polysaccharides and jiaogulan saponins exert cancer
- preventive effects by shaping the gut microbiota and microenvironment in Apc(Min/+) 981
- 982 mice. Pharmacol Res 148, 104448 (2019).
- 139. Li, S., Fu, C., Zhao, Y. & He, J. Intervention with alpha-Ketoglutarate 983
- Ameliorates Colitis-Related Colorectal Carcinoma via Modulation of the Gut 984
- 985 Microbiome. Biomed Res Int 2019, 8020785 (2019).
- 140. Fernandez, J. et al. A Galacto-Oligosaccharides Preparation Derived From 986
- 987 Lactulose Protects Against Colorectal Cancer Development in an Animal Model.
- 988 Front Microbiol 9, 2004 (2018).
- 141. Mudd, A.M. et al. Chemoprevention of Colorectal Cancer by Anthocyanidins 989
- 990 and Mitigation of Metabolic Shifts Induced by Dysbiosis of the Gut Microbiome.
- Cancer Prev Res (Phila) 13, 41-52 (2020). 991
- 992 142. Wu, J.C. et al. Polymethoxyflavones prevent benzo[a]pyrene/dextran sodium
- sulfate-induced colorectal carcinogenesis through modulating xenobiotic metabolism 993
- 994 and ameliorate autophagic defect in ICR mice. Int J Cancer 142, 1689-1701 (2018).
- 995 143. Wang, X. et al. Structural shift of gut microbiota during chemo-preventive
- 996 effects of epigallocatechin gallate on colorectal carcinogenesis in mice. World J
- 997 Gastroenterol 23, 8128-8139 (2017).
- 998 144. Chou, Y.C. et al. Boswellia serrata resin extract alleviates azoxymethane
- (AOM)/dextran sodium sulfate (DSS)-induced colon tumorigenesis. Mol Nutr Food 999
- 1000 Res **61** (2017).
- 145. Fukuda, M. et al. Prebiotic treatment reduced preneoplastic lesions through 1001
- the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model. J 1002
- 1003 Clin Biochem Nutr 49, 57-61 (2011).
- 146. Oh, N.S., Lee, J.Y., Kim, Y.T., Kim, S.H. & Lee, J.H. Cancer-protective effect 1004
- of a synbiotic combination between Lactobacillus gasseri 505 and a Cudrania 1005
- tricuspidata leaf extract on colitis-associated colorectal cancer. Gut Microbes 12, 1006
- 1785803 (2020). 1007
- 1008 147. Rudd, D.A. et al. Mapping insoluble indole metabolites in the gastrointestinal
- environment of a murine colorectal cancer model using desorption/ionisation on 1009
- 1010 porous silicon imaging. Sci Rep 9, 12342 (2019).
- 148. Zhang, J. et al. A Functional Food Inhibits Azoxymethane/Dextran Sulfate 1011
- Sodium-Induced Inflammatory Colorectal Cancer in Mice. Onco Targets Ther 14, 1012
- 1013 1465-1477 (2021).

- 149. Piazzi, G. et al. A Mediterranean Diet Mix Has Chemopreventive Effects in a 1014
- Murine Model of Colorectal Cancer Modulating Apoptosis and the Gut Microbiota. 1015
- Front Oncol 9, 140 (2019). 1016
- 150. Li, F. et al. Modulation of colon cancer by nutmeg. J Proteome Res 14, 1937-1017
- 1018 1946 (2015).
- 151. Chen, L. et al. Chemoprevention of colorectal cancer by black raspberry 1019
- anthocyanins involved the modulation of gut microbiota and SFRP2 demethylation. 1020
- 1021 Carcinogenesis 39, 471-481 (2018).
- 152. Fernandez, J., Garcia, L., Monte, J., Villar, C.J. & Lombo, F. Functional 1022
- Anthocyanin-Rich Sausages Diminish Colorectal Cancer in an Animal Model and 1023
- Reduce Pro-Inflammatory Bacteria in the Intestinal Microbiota. Genes (Basel) 9 1024
- 1025 (2018).
- 1026 153. Wang, C.Z. et al. Role of intestinal microbiome in American ginseng-mediated
- colon cancer prevention in high fat diet-fed AOM/DSS mice [corrected]. Clin Transl 1027
- 1028 Oncol 20, 302-312 (2018).
- 154. Hu, Y. et al. Manipulation of the gut microbiota using resistant starch is 1029
- associated with protection against colitis-associated colorectal cancer in rats. 1030
- 1031 Carcinogenesis 37, 366-375 (2016).
- 155. Yu, C. et al. American ginseng significantly reduced the progression of high-1032
- fat-diet-enhanced colon carcinogenesis in Apc (Min/+) mice. J Ginseng Res 39, 230-1033
- 237 (2015). 1034
- 156. Gao, Z. et al. Probiotics modify human intestinal mucosa-associated 1035
- microbiota in patients with colorectal cancer. Mol Med Rep 12, 6119-6127 (2015). 1036
- 1037 157. Zhang, J.W. et al. Preoperative probiotics decrease postoperative infectious
- complications of colorectal cancer. Am J Med Sci 343, 199-205 (2012). 1038
- 158. Aisu, N. et al. Impact of perioperative probiotic treatment for surgical site 1039
- infections in patients with colorectal cancer. Exp Ther Med 10, 966-972 (2015). 1040
- 159. Liu, Z. et al. Randomised clinical trial: the effects of perioperative probiotic 1041
- 1042 treatment on barrier function and post-operative infectious complications in colorectal
- cancer surgery a double-blind study. Aliment Pharmacol Ther 33, 50-63 (2011). 1043
- 160. Gianotti, L. et al. A randomized double-blind trial on perioperative 1044
- 1045 administration of probiotics in colorectal cancer patients. World J Gastroenterol 16,
- 1046 167-175 (2010).

- 161. So, W.K.W. et al. Effects of a Rice Bran Dietary Intervention on the 1047
- Composition of the Intestinal Microbiota of Adults with a High Risk of Colorectal 1048
- 1049 Cancer: A Pilot Randomised-Controlled Trial. Nutrients 13 (2021).
- 162. Xie, X. et al. Effects of prebiotics on immunologic indicators and intestinal 1050
- microbiota structure in perioperative colorectal cancer patients. Nutrition 61, 132-142 1051
- 1052 (2019).
- 163. Polakowski, C.B., Kato, M., Preti, V.B., Schieferdecker, M.E.M. & Ligocki 1053
- 1054 Campos, A.C. Impact of the preoperative use of synbiotics in colorectal cancer
- 1055 patients: A prospective, randomized, double-blind, placebo-controlled study. Nutrition
- 1056 **58**, 40-46 (2019).
- 164. Hibberd, A.A. et al. Intestinal microbiota is altered in patients with colon cancer 1057
- and modified by probiotic intervention. BMJ Open Gastroenterol 4, e000145 (2017). 1058
- 1059 165. Worthley, D.L. et al. A human, double-blind, placebo-controlled, crossover trial
- of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, 1060
- inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. Am J Clin 1061
- 1062 Nutr **90**, 578-586 (2009).
- 166. Brown, D.G., Borresen, E.C., Brown, R.J. & Ryan, E.P. Heat-stabilised rice 1063
- 1064 bran consumption by colorectal cancer survivors modulates stool metabolite profiles
- 1065 and metabolic networks: a randomised controlled trial. Br J Nutr 117, 1244-1256
- 1066 (2017).
- 167. Nunez-Sanchez, M.A. et al. Gene expression changes in colon tissues from 1067
- colorectal cancer patients following the intake of an ellagitannin-containing 1068
- pomegranate extract: a randomized clinical trial. J Nutr Biochem 42, 126-133 (2017). 1069
- 168. Nunez-Sanchez, M.A. et al. MicroRNAs expression in normal and malignant 1070
- colon tissues as biomarkers of colorectal cancer and in response to pomegranate 1071
- 1072 extracts consumption: Critical issues to discern between modulatory effects and
- potential artefacts. Mol Nutr Food Res 59, 1973-1986 (2015). 1073
- 169. Chen, C.C. et al. Oral inoculation of probiotics Lactobacillus acidophilus NCFM 1074
- 1075 suppresses tumour growth both in segmental orthotopic colon cancer and extra-
- intestinal tissue. Br J Nutr 107, 1623-1634 (2012). 1076
- 170. Bellville, J.W., Swanson, G.D., Miyake, T. & Agleh, K.A. Respiratory 1077
- stimulation observed following ethanol ingestion. West J Med 124, 423-425 (1976). 1078

- 171. Shinohara, K., Ohashi, Y., Kawasumi, K., Terada, A. & Fujisawa, T. Effect of 1079
- apple intake on fecal microbiota and metabolites in humans. Anaerobe 16, 510-515 1080
- (2010).1081
- 172. Schwartz, S.E. et al. Sustained pectin ingestion: effect on gastric emptying 1082
- and glucose tolerance in non-insulin-dependent diabetic patients. Am J Clin Nutr 48, 1083
- 1413-1417 (1988). 1084
- 173. Annunziata, G. et al. Effect of Grape Pomace Polyphenols With or Without 1085
- Pectin on TMAO Serum Levels Assessed by LC/MS-Based Assay: A Preliminary 1086
- 1087 Clinical Study on Overweight/Obese Subjects. Front Pharmacol 10, 575 (2019).
- 174. Glinsky, V.V. & Raz, A. Modified citrus pectin anti-metastatic properties: one 1088
- bullet, multiple targets. Carbohydr Res 344, 1788-1791 (2009). 1089
- 175. Warburg, O. On the origin of cancer cells. Science **123**, 309-314 (1956). 1090
- 1091 176. Roediger, W.E. Role of anaerobic bacteria in the metabolic welfare of the
- colonic mucosa in man. Gut 21, 793-798 (1980). 1092
- 177. Khoo, H.E., Azlan, A., Tang, S.T. & Lim, S.M. Anthocyanidins and 1093
- anthocyanins: colored pigments as food, pharmaceutical ingredients, and the 1094
- potential health benefits. Food Nutr Res 61, 1361779 (2017). 1095
- 1096 178. Reglero, C. & Reglero, G. Precision Nutrition and Cancer Relapse Prevention:
- 1097 A Systematic Literature Review. *Nutrients* **11** (2019).
- 179. Toledo, E. et al. Mediterranean Diet and Invasive Breast Cancer Risk Among 1098
- Women at High Cardiovascular Risk in the PREDIMED Trial: A Randomized Clinical 1099
- Trial. JAMA Intern Med 175, 1752-1760 (2015). 1100
- 180. Bamia, C. et al. Mediterranean diet and colorectal cancer risk: results from a 1101
- 1102 European cohort. *Eur J Epidemiol* **28**, 317-328 (2013).
- 181. (2018). 1103

- 182. Henderson, A.J. et al. Chemopreventive properties of dietary rice bran: current 1104
- status and future prospects. Adv Nutr 3, 643-653 (2012). 1105

Figure legends Figure 1. Flow chart of the search and selection process. Figure 2. Distribution of the studies analyzed. a. Preclinical and clinical studies. b and c. Pre-, pro-, symbiotics and food in b. preclinical and c. clinical studies. d. Strains used as probiotics in preclinical studies. e. Prebiotics used in preclinical studies. f. Strains used as probiotics in clinical studies. g. Prebiotics used in clinical studies. * More than 1 pro- and prebiotic is used in some studies.

Table 1. Details of the search strategy used.

Field	Key words	Boolean Operator
Title	(Cancer* OR carcino* OR tumor* OR onco*)	AND
Title/Abstract	(colon* OR colorect*)	AND
Title/Abstract	(microbi* OR dysbi*)	AND
Title/Abstract	(chemo* OR immuno* OR car-t* OR radium* OR surgery* OR therapy*	AND
Title/Abstract	(nutrition* OR diet* OR food* OR probio* OR prebio* OR symbio*)	NOT
Type of publication	(Biography OR Comment OR Duplicate publication OR Editorial OR Guideline OR Interview OR News OR Personal Narrative OR Published Erratum OR Retracted Publication OR Retraction of Publication OR Meta-Analysis OR Review OR Systematic Review)	

Table 2. Summary of the results of the articles analyzed.

Intervention	Type of cancer	Type of study	Impact on microbiota	Mechanism	Effect on the tumor	Ref	Scientific quality
			Preclinical studies				
			Probiotics				
Probiotic: Akkermansia muciniphila	Subcutane ous, syngeneic model of colon cancer	Female BALB/c mice injected subcutaneousl y with CT26 cells in combination or not with IL-2	↑ diversity and Akkermansia, Allstipes and Lactobacillus	↑ necrosis, ↓ proliferation, and ↑ tumor apoptosis. ↑ CTL and ↓ Treg recruitment. ↑ IFN-γ and IL-2 in the tumor and ↑ TNF-α in serum, together with ↓ TGF-β. The Amuc protein effects through TLR2.	↓ tumor volume and weight and ↑ survival time	115	4
Probiotic: VSL#3, is composed of: Lactobacillus plantarum, Lactobacillus delbrueckii subsp. Bulgaricus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacteriu m breve, Bifidobacteriu m longum, Bifidobacteriu m infantis and Streptococcus salivarius subsp. Thermophilus.	Gnobiotic model of CRC associated with colitis and inflammati on	129/SvEv deficient in IL10 treated with AOM	↓ Verrucomicrobia and ↑ Proteobacteria in the mucosa. ↓ Bacteroidetes in feces	↓ Clostridium in the mucous membrane	penetrance, invasiveness, histological grade, tumor volume and number of tumors	-116-	4
Inactivated	CRC	Syngeneic	↓ Proteobacteria		↓ of tumors	76	3

probiotic: Lactobacillus acidophilus lysates (Phylum Firmicutes)	associated with colitis	male BALB/C treated with AOM and DSS		↑ Th1 lymphocytes (CD3 + CD4 + IFN-γ+) and M1 macrophages (CD11b + F4/80 + CD86+) in mesenteric lymphoid nodules. In combination with anti CTLA-4 ↑ TCD8+ effector memory (CD44 + CD8 + CD62L+), ↓ Treg (CD4 + CD25 + Foxp3+) and M2 macrophages (F4/80 + CD206+) in the tumor microenvironm ent. In addition to ↑ IL-2 in nodules and plasma and plasma IFN-γ	and trend towards ↑ survival in combination with CTLA-4 inhibitors		
Probiotic: Lactobacillus rhamnosus, Lactobacillus plantarum and Pediococcus pentosaceus	Early colon carcinoge nesis	Male Wistar rats treated with DHM	↑ lactic acid bacteria	↓ weight loss, fecal pH, liver transaminases and fecal enzyme normalization	↓ aberrant intestinal crypts, especially with <i>L. rhamnosus</i> .	117	3
Probiotic: Enterococcus faecalis, Bifidobacteriu m longum and Lactobacillus acidophilus (Bifico)	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ Lactobacillus.↓ Desulfovibrio, Mucispirillum, and Odoribacter	r colon size. ↓ IL-1β, IL-6, COX-2 and TNF-α, in addition to PGE2 production. ↓ Cxcl1, Cxcl2, Cxcl3, Cxcl5 and Ccl7.	↓ number and volume of tumors	118	3
Probiotic: Akkermansia muciniphila or its specific membrane protein Amuc_1100	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	NR	↑ cytotoxic TCD8 in mesenteric nodules. ↑ TCD8-TNF-α+ and ↓ TCD8- PD-1+. ↓ TCD8 and Ki67 in colon.	malignancy score, tumor formation and area	36	2
Probiotic: Lactobacillus rhamnosus M9	CRC associated with colitis	Male 6- C57BL/6NCrSl c mice treated with AOM and DSS	↑ diversity of the flora and ↑ of Blautia, Akkermansia, Lactobacillus and Bifidobacterium	↓ PCNA, pSTAT3, pAKT.↓ CD68+ and CD163+ in subserosa.	↓ number and size of tumors. ↓ inflammatory and fibrotic score.	119	2
Probiotic: Butyricicoccus pullicaecorum	CRC associated with colitis	male BALB/cByJNar I treated with DHM	NR	↑ SLC5A8 and GPR43	↓ infiltration, anal bleeding, and CEA levels	120	2

Probiotic: Lactobacillus plantarum VD23 Lactobacillus plantarum C28 Lactobacillus plantarum MS18 Lactobacillus salivarius MS3 Lactobacillus salivarius MS6 Lactobacillus salivarius MS6	Early colon carcinoge nesis	Male Wistar rats treated with DHM	NR	↑IL-18	proliferation, volume and total number of tumors. ↑ colon length (nonsignificant results)	121	2
Probiotic: Lactobacillus bulgaricus	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	NR	↓ IL-6, TNF-α, IL-17, IL-23 and IL-1β and ↑ IFN-γ in healthy and tumor intestinal tissue	↓ mean tumor volume and size. ↓ pathological severity score and ↑ colon length.	122	2
Probiotic: Bifidobacteriu m and Lactobacillus	Subcutane ous, syngeneic model of colon cancer	Female BALB/c mice injected subcutaneousl y with CT26 cells	↑ Alloprebotella, Citrobacter, Prevotellaceae_UC G-001, Roseburia, Thalassospira, Erysipelatoclostridiu m and Lachnospiraceae_U CG-006. ↓ Desulfovibrio, Anaerotruncus, Mucispirillum, Odoribacter. and Escherichia- Shigella. ↑ Bacteroides_chinchil lae and Helicobacter_ Ganmani. ↓ Escherichia coli, Lachnospiraceae bacterium_COE1, Bacteroides vulgatus and Lachnospiraceae bacterium_10-1	NR	No change in tumor volume	123	2
Probiotic: Lactobacillus casei variety rhamnosus (Lcr35)	Subcutane ous, syngeneic model of colon cancer	Male BALB/c mice injected subcutaneousl y with CT26 cells and treated with FOLFOX (5-fluorouracil, leucovorin, and Lactobacillus casei oxaliplatin).	↑ <i>Firmicutes</i> and <i>Bacteroidete</i> s	↓ severe diarrhea and mucositis. ↓ apoptotic cells, NF-κB and BAX. ↓ TNF-α and IL6.	Unchanged	124	2
Probiotic: Faecalibacteri um prausnitzii	Subcutane ous model, colon cancer with cachexia	Male CD2F1 mice injected subcutaneousl y with C26 (I understand this refers to CT26, although it is	NR	Improvement of various parameters related to the intestinal barrier, but not significant	↓ tumor mass, not significant	125	2

		mak and alti- all					
		not specified).					
Probiotic: Lactobacillus casei BL23	CRC associated with colitis	C57BL/6 WT females treated with AOM and DSS	↑ Lactobacillus zeae	↓ Ki67. ↑ Bik	tumor volume, number of tumors and histological malignancy	126	2
Probiotic: Lactobacillus reuteri	CRC associated with colitis	Hdc-/- BALB/c male BALB/c treated with AOM and DSS	NR	↓ tumor zone KC, IL22, IL6, TNF-α, IL-1-α. ↓ serum KC, IL22, IL6. ↓ CD11b+Gr-1+	↓ number of tumors	127	2
Probiotic: VSL#3, is composed of: Lactobacillus plantarum, Lactobacillus delbrueckii subsp. Bulgaricus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacteriu m breve, Bifidobacteriu m longum, Bifidobacteriu m infantis and Streptococcus salivarius subsp. Thermophilus.	CRC associated with colitis	Male BALB/c WT treated with AOM and DSS with Western diet and metformin.	NR	Metformin + VSL#3 = ↓ Ki67, F4/80	Metformin and metformin+V SL#3 = ↓ number of tumors	128	2
Probiotic: Lactobacillus paracasei DTA81	Early colon carcinoge nesis	male BALB/c WT treated with DHM	↑ Ruminiclostridium and ↑ fecal acetic acid* and short- chain short acids* (*poorly performed comparator groups)	↓ IL-6, IL-17, and PCNA in colonic homogenates	Show no change	129	1
Probiotic: Lactobacillus rhamnosus	Early colon carcinoge nesis	male BALB/c WT treated with DHM	↑ <i>Romboutsia</i> and Turicibacter	↑IL4, IL-10 IL- 6, IL-17, TNF- α, IFN-y, c- MYC and P-53 in colonic homogenates	Show no change	129	1
Probiotics: Lactobacillus acidophilus, Lactobacillus rhamnosus and Bifidobacteriu m bifidum	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ Lactobacillus, Bifidobacterium, Allobaculum, Clostridium XI, and Clostridium X III	tolitis, toliculating levels of RANTES and eotaxin; toliculation likk and TNF-α with † IL-10	↓ incidence and number of tumors	130	1
			Prebiotics			,	
Prebiotic: Fructooligosac charide/inulin	Gnobiotic model of CRC associated with colitis	BALB/C mice (gender undefined) treated with AOM and DSS	NR	↑ histone 3 and ↓ HDAC activity. ↑ levels of Fas and active caspase 3. ↓ of p21, p27 and Ki-67.	↓ histological grade, volume and number of tumors	66	5

Prebiotic: Pectin	Subcutane ous, syngeneic model of colon cancer	Female C57BL/6 WT mice injected with MC38 cells. With humanized microbiota from healthy humans or patients, anti- PD-1 treatment.	↑ diversity, ↑ Lactobacillaceae, Bifidobacteriaceae, Erysipelotrichaceae, Ruminococcaceae, Faecalibacterium, and Holdemania. ↑ percentage Firmicutes/Bacteroid etes. ↑ acetate and butyrate.	↑ TCD4+, TCD8+ and TCD8+IFNγ+ tumor infiltration	↓ tumor volume and size	131	4
Prebiotic: Mucin and inulin	Subcutane ously transplant ed colon cancer (MC-38)	Syngeneic C57BL/6 mice	↑ <i>Clostridium</i> cluster XIVa	↑ of MHC class I and MHC class II expression in CD	Inulin causes ↓ tumor volume. No change in tumor volume with Mucin	132	4
Prebiotic: food extract: Evodiamine	CRC associated with colitis	C57BL/6 WT treated with HFD, AOM and DSS	↑ Campylobacter, Bifidobacterium and Lactobacillus. ↓ E. faecalis and E. coli	↓ IL-1, IL- 6 and circulating TNF-α and in colonic tissue ↓ p-STAT3 and p-P65	↑ survival, ↓ tumor diameter and percentage weight/lengt h of intestine. ↓ pathological score and proliferation, ↑ apoptosis.	133	3
Prebiotic: Food extract: Fucoxanthin	CRC associated with colitis	ICR WT male treated with AOM and DSS	↑Lachnospiraceae and ↓ <i>Bacteroidales</i> and <i>Rikenellaceae</i>	↑ caspase 3	↓ size and number of colorectal adenomas and total tumors	134	3
Prebiotic: Food extract: Menthol	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ in butyrate- producing bacteria (<i>Allobaculum</i> , <i>Roseburia</i> and <i>Intestinimonas</i>) and fecal ↑ butyrate	$\downarrow \text{ expression} \\ \text{ of } \beta\text{-catenin,} \\ \text{Ki67, IL-6,} \\ \text{TNF-}\alpha \text{ and} \\ \text{MPO.} \downarrow \\ \text{infiltration of immune cells} \\ \text{in the spleen,} \\ \uparrow \\ \text{IL10 in the} \\ \text{distal colon} \\$	↓ the number of 1- 3 mm adenomas in a dose- dependent manner and damage scales.	135	2
Prebiotic: Chitosan and low molecular weight citrus pectins encapsulating bilberry anthocyanins	Subcutane ously transplant ed colon cancer (MC-38)	Female C57BL/6 mice	↑ <i>Lachnospiraceae</i> (Clostridiales) and diversity	They suggest a ↑ of SCFA and TCD4+ and TCD8+ infiltration of the tumor, but are not significant.	↓ tumor volume in combination with PD-L1 inhibitors.	136	2
Prebiotic: Canmei formula	CRC associated with colitis	C57BL/6 WT females treated with AOM and DSS and HFD	↑ Turicibacter, Bacteroides, Bacteroidaceae, Faecalibaculum, Erysipelatoclostridiu m and Staphylococcus	↓ serum levels of IL-17 and NF-кB	↓ tumor incidence	137	2
Prebiotic: Polysaccharid es from Ganoderma lucidum and saponin from	Prevention of colon cancer of genetic origin	ApcMin+/- male mice	↑ bacteria producing SCFA and ↓ of sulfur-reducing bacteria	Shift from M1 to M2 macrophages. Reversal of expression, E- cadherin/N-	↓ number and size of polyp	138	2

Gynostemma pentaphyllum				cadherin ratio and ↓ oncogenic signaling. ↑ signaling of Gprotein coupled- receptors due to modulation of histone deacetylases, PYY and PPARγ expression.			
Prebiotic α- ketoglutarate	CRC associated with colitis	C57BL/6 WT females treated with AOM and DSS	↑ diversity. ↑ Akkermansia, Butyricicoccus, Clostridium and Ruminocococus. ↓ Escherichia and Enterococcus.	\downarrow IL-6, IL-22, TNF- α , and IL-1 β	↓ tumor frequency, size, and stage.	139	2
Prebiotic: Lactulose- derived galacto- oligosaccharid es	CRC associated with colitis	Male Rattus norvegicus F344 rats treated with AOM and DSS	↑ propionate. ↑ diversity of flora, anti-inflammatory: Bifidobacterium, Bacteroidaceae, Prevotellaceae, Acidaminococcaceae e, Bifidobacteriaceae, Peptococcaceae, Oscillospiraceae and ↓ of pro- inflammatory: Lachnospiraceae, Eubacteriaceae, Acholeplasmatacea e and Firmicutes/Bacteroid etes %.	↑ cecum length	↓ number and volume of polyps	140	2
Prebiotic: Anthocyanidin s wrapped or not in exosomes.	CRC associated with dysbiosis	ApcMin/+ Mice Inoculated with Bacteroides fragilis	NR	↑ in the liver, but not in the tumor, of phase I enzymes CYP1A1 and CYP1B1 and ↓ of phase II enzymes GSTM1 and SULT1	↓ number of tumors	141	1
Prebiotic: polymethoxyfl avones	CRC associated with colitis	ICR WT males treated with benzo[a]pyren e and DSS	↑ Sphingobacteriacea e, Gammaproteobacter ia, Ruminococcaceae and Blautia.↓ Bacilli, Parabacteroides, Lactobacillus Ruminis (without statistical analysis)	↑ colon size. ↓ hepatic and renal toxicity. ↓ BaP-7,8- dihydrodiol- 9,10-epoxide- DNA binding. ↓ genes for inflammation, metastasis and ↑ antioxidants.	↓ hyperplasias , adenoma and adenocarcin omas	142	1
Prebiotic: Epigallocatech in gallate (EGCG)	CRC associated with colitis	FVB/N WT female treated with benzo[a]pyren e and DSS	↑ Lactobacillus, Fusobacterium, Ruminococcus,↓ Bacteroides, Anaerotruncus	NR	↓ volume and number of tumors and pre- cancerous lesions	143	1
Prebiotic: Boswellia	CRC associated	ICR WT male treated with	↑ Clostridiales spp and ↓ Bacteroidales	↓ NF-κB, PCNA. ↑	↓ number of tumors	144	1

serrata resin	with colitis	AOM and DSS		colon length			
Prebiotic: Germinated barley extract	CRC associated with colitis	AOM-treated male Fisher 344 rats	NR	↓ TLR4 and COX2	↓ aberrant crypts	145	1
			Symbiotics				
Symbiotic: Clostridium butyricum and prebiotic dextran	Subcutane ous and orthotopic model of colon cancer	CT26luc and ApcMin+/-	↑ Muribaculaceae, Bacteroides, Mucispirillum, Alloprevotella, Lachnospiraceae, and Ruminococcaceae	↑ iso-butyrate, butyrate, iso- valerate, propionate, valerate, iso- hexanoate, and hexanoate, ↓ dysbiosis	effectivenes s of capecitabine and diclofenac, ↓ tumor size of 74% /in combination with diclofenac, while diclofenac only 11%, abdominal invasion, ↑ apoptosis	96	5
Symbiotic: Lactobacillus gasseri 505 (LG) and leaf extract of Cudrania tricuspidata (CT) in fermented milk called FCT	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ Lactobacillus, Bifidobacterium, and Akkermansia associated with ↑ SCFA and ↓ Staphylococcus	↓ TNF-α, IFN- γ, IL-1β, IL-6, iNOS and COX-2. ↑ IL-4 and IL-10. ↑ MUC2, TFF3 and ZO-1. ↑ p53, p21, and Bax. ↓ Bcl-2 and Bcl-xL. ↓ β- Catenin, NF- κB and ↑ IκB-α	↓ incidence of tumors and dysplasia. ↑ colon length	146	3
	1		Food				ı
Western diet, antibiotics and Enterococcus faecalis.	Model of CRC recurrence after surgery	Male BALB/c mice inoculated with CT26 after resection and anastomosis	Western diet = ↑ E. faecalis. Western diet associated with tumors ↑ Proteus, Akkermansia and Trabulsiella. ↓ in Bacteroides, Roseburia and Ruminococcus. Inoculation with E. faecalis = ↑ Proteus, Enterococcus, Trabulsiella Akkermansia and Clostridium and ↓ Roseburia.	NR	↑ tumor formation with Western diet and E. faecalis. ↑ distant metastasis with Western diet (not significant).	105	4
Food extract: selfish Muricidae: 1. marine extract (NE) 2. metabolite of the extract 6-bromoisatin (6-Br)	CRC genotoxic	AOM-treated male C57BL/6 WT	NR	6-Br =↓ tumor proliferation. NE = ↓ proliferation and ↑ apoptosis in crypts.	6-Br =↓ number of aberrant crypts and tumors. NE = ↓ number of tumors	147	4
Functional food: extract of 55 different foodstuffs mixed	CRC associated with colitis	AOM- and DSS-treated male BALB/c mice	Desulfovibrio and Ruminococcaceae and ↑ from Bacteroides, Ruminiclostridium_6, Holde manella, Clostridium_sensu_	Improved intestinal barrier and body weight maintenance. ↓ IL-6 and TNF-α.↑ in	↓ number and size of tumors. ↑ survival	148	3


			stricto_1, Allobaculum and Parasutterella. ↓ of deuteroporphyrin IX, citrulline, and diferuloylputrescine, and ↑-acid acetic, ascorbic, palmitic, quinic, ursocholic, branched amino acids, rosmaridiphenol and scillirosidine	the proportion of total T cells, CD3+CD4+, CD3+CD8+, and IFN-γ- producing CD4+ T cells.			
Diet: - low fat (LFD) - high fat (HFD) - a mixture of one of them with Mediterranean (MD). This being a mixture of ω-3 polyunsaturate d fatty acids (PUFA), eicosapentano ic acid and polyphenols.	CRC genotoxic	A/J WT male treated with AOM	MD improves dysbiosis with an HFD, but worsens it with an LFD.	MD ↑ apoptosis in HFD, and especially in LFD. MD ↑ eicosapentano ic acid (EPA), especially in LFD.	MD↓ incidence in HFD, but especially in LFD	149	3
Food extract: Nutmeg	Prevention of colon cancer of genetic origin	C57BL/6J WT and ApcMin+/- Male Mice	NR	↓ in urine of cresol sulphate and glucuronide, indoxyl sulphate and phenyl sulphate.↓ colon and liver IL6.↓ ALT and amylase.↑ LPE 18:0, LPC 18:0, azelaic acid, sebacic acid, palmitolcarniti ne and oleocarnitine. ↑ lipid metabolism gene expression in the colon and liver	↓ tumor volume and number of tumors	150	3
Food extract: Anthocyanin extract from blackberries.	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ Eubacterium rectale, Faecalibacterium prausnitzii and Lactobacillus. ↓ Desulfovibrio and Enterococcus spp.	↑ SFRP2 triggers the ↓ of DNMT1 and p-STAT3. In addition to ↓ IL-1β, IL-6, II- 10, COX-2 and TNF-α.	↓ number of tumors	151	2
Food extract: Anthocyanins extracted from strawberries and blackberries	CRC associated with colitis	Male Rattus norvegicus F344 rats treated with AOM and DSS	↓ Bilophila wadsworthia	Improved plasma reducing capacity	↓ number of tumors	152	2
Food extract: American	CRC associated	A/J male treated with	Improving dysbiosis	NR	↓ number of tumors and	153	2


Ginseng	with colitis	AOM and DSS			histological	l	
Ginserig	With Contis	and HFD			malignancy		
Food extract and prebiotic: Green tea extract (EGCG) and resistant starch	CRC associated with colitis	Male Sprague- Dawley rats treated with AOM and DSS	↑ Parabacteroides, Barnesiella, Ruminococcus, Marvinbryantia and Bifidobacterium. ↑ acetate, butyrate and propionate.	↑ GPR43.↓ COX-2, NF- kB, TNF-α and IL-1β.	Resistant starch = ↓ number of tumors and adenocarcin oma formation	154	2
Food extract: American Ginseng	Prevention of colon cancer of genetic origin with a Western diet	Male ApcMin+/- mice on high- fat diet	NR	↓ IL-1α, IL-1β, IL6, TNF-α, G- CSF and GM- CSF	↓ tumor volume and number of tumors	155	2
			Clinical studies				
			Probiotics				
Probiotic: Bifidobacteriu m longum, Lactobacillus acidophilus and Enterococcus faecalis	Patients with CRC who have previously undergone radical surgery and who are about to undergo further surgery.	Randomized clinical trial Peri-surgery placebo (n=11), probiotic (n=11). Healthy control patients (n=11).	↑ Enterococcus and ↓ Peptostreptococcus, Comamonas, Fusobacterium	NR	NR	156	2
Probiotic: Bifidobacteriu m longum, Lactobacillus acidophilus and Enterococcus faecalis	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Randomized clinical study Placebo (n=30), preoperative probiotic (n=30)	↑ preoperative percentage Bifidobacterium/E. coli	↑ IgG and sIga in serum.↓ endotoxins, D- lactic acid, IL- 6 and CRP	↓ incidence of post- surgery infections	157	2
Probiotic: Enterococcus faecalis T110, Clostridium butyricum TO- A and Bacillus mesentericus	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Clinical study Control (n=81), Probiotic (n=75)	NR	↓ incisional infections and reduced acute inflammation after surgery	NR	158	2
Probiotic: Lactobacillus plantarum, Lactobacillus acidophilus and Bifidobacteriu m longum	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Randomized double-blind clinical study. Placebo (n=50), perioperative probiotic (n=50).	↑ diversity. ↑ Bifidobacterium and Lactobacilli. ↓ Enterobacteriaceae, Pseudomonas and Candida	↑ claudin1, JAM1 and occludin	NR	159	2
Probiotic: Bifidobacteriu m longum (BB536) and Lactobacillus johnsonii (La1)	CRC patients whose tumor could be removed	Randomized double-blind clinical study. Placebo (n=10), probiotic	La1 = ↑ La1 in mucosa and feces. ↓ Enterobacteriaceae	↑ CD3, CD4, CD8 and naive and memory lymphocytes. ↓ CD83-123 markers,	NR	160	2

	by surgery and who are scheduled for surgery	mixture at a dose of 107 (n=11) and probiotic mixture at a dose of 109 (n=11). Perisurgery treatment		CD83-HLADR, and CD83-11c			
Probiotic: Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacteriu m lactis, Bifidobacteriu m bifidum, Bifidobacteriu m breve, Streptococcus thermophilus	Stage III colorectal adenocarc inoma	Randomized clinical study of 78 patients with colorectal carcinoma with surgery	NR	NR	↓ number of complication s associated with surgery	74	1
	•		Prebiotics				,
Prebiotic: food extract: evodiamine	CRC patients	CRC patients undergoing colonoscopies vs. healthy patients without any colorectal disease	↑ E. faecalis and E. coli↓ Campylobacter, Bifidobacterium and Lactobacillus in CRC. ↑ Endotoxin and D-lactic acid in CRC.	↑ pSTAT3 in cancerous vs. peritumor biopsies	proliferation, p-STAT3 and p-P65 after incubation with evodiamine in colon cancer cell lines HCT- 116 and SW-480	133	3
Prebiotic: Rice bran	Patients at high risk of developing CRC	Randomized, double-blind, placebo- controlled trial (placebo = 19, treatment = 20). Placebo = rice powder, rice bran treatment. 30 g every 24h, for 24 weeks.	↑ Firmicutes and Lactobacillus	NR	NR	161	3
Prebiotic: fructo- oligosaccharid es, xylooligosacch arides, polydextrose, and resistant dextrin	CRC patients requiring radical surgery (peri- surgery: pre- and post- surgery are analyzed).	Randomized double-blind clinical study with 140 CRC patients (control = 70; prebiotics = 70)	Pre-surgery = ↑ Bifidobacterium and Enterococcus, ↓ Bacteroides. Post-surgery = ↑ Bifidobacterium and Escherichia- Shigella, ↓ Enterococcus	Pre-surgery =	NR	162	2
	I		Symbiotics	<u> </u>		1	<u> </u>
Symbiotic: Maltodextrin as placebo	CRC patients to be treated	Prospective, double-blind, randomized,	NR	↓ plasma IL6 and CRP levels. ↓ post-	3 deaths in the control group and	163	2

and treatment with Simbioflora® (6g fructooligosac charide, plus Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus HN001, Lactobacillus casei LPC-37 and Bifidobacteriu m lactis HN019).	with surgery. Stages I-III	placebo- controlled clinical study (placebo; n = 36. Treatment; n = 37).		surgery infections, antibiotic use and hospital stay.	none in the treatment group.		
Symbiotic: Bifidobacteriu m lactis BI-04, Lactobacillus acidophilus NCFM and inulin	Stage I-III CRCs undergoin g surgery	Clinical trial 21 healthy controls (colonoscopy), 15 CRC patients (8 non- intervention, 7 probiotic)	↑ Firmicutes, Clostridiales spp and Faecalibacterium	NR	NR	164	1
			Pre-, pro- and symbic	otic			
Prebiotic (resistant starch) probiotic (Bifidobacteriu m lactis) or combination of both (symbiotic)	Study in healthy subjects for CRC prevention	Randomized double-blind clinical study with crossover treatments. Healthy subjects, n = 17, for 16 weeks, 4 weeks per arm (placebo, prebiotic, probiotic and symbiotic).	Symbiotic = ↑ <i>Lachnospiraceae</i> spp.	No changes in fecal ammonium, SCFA or circulating cytokines. No epithelial changes.	NR	165	3
	ı		Food				
Food extract: Rice bran	CRC patients who have undergone surgery.	Randomized clinical study (control; n = 10. 30g/day rice bran; n = 9)	NR	carbohydrate, lipid, amino acid, cofactor and vitamin metabolism	NR	166	2
Food extract: Pomegranate extract with high ellagitannin content	CRC patients whose tumor could be removed by surgery	Randomized clinical study. Control (n=10), PE (n=35)	NR	↓ CD44 and CTNNB1 in adjacent healthy tissue and tumor. ↓ CDKN1A, EGFR and TYMS in tumor.	NR	167	2
Food extract: Pomegranate extract with high ellagitannin content	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Randomized double-blind clinical study Control (n=11), pomegranate extract #1 (n=19) and #2 (n=16)	NR	Modulation of miRNAs	NR	168	2

Increase/activation has been indicated as (↑) and reduction/inhibition as (↓). NR - Not reported. Ref = References





Madrigal-Matute & Banon-Escandell, Fig. 2